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"Life is not measured by the numbers of breaths we take, 
but by the moments that take our breath away" 
 
-unknown origin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family  
 

  
ABSTRACT 
Background: Endometrial cancer is the most common gynecological cancer in the 
industrialized world, constituting 4.5% of all cancer in Swedish women. Standard surgery is 
hysterectomy and bilateral salpingo-oophorectomy, with or without lymphadenectomy, 
depending on the estimated risk of lymph node metastases. Adjuvant therapy is given, 
depending on the estimated risk of adverse outcome. Numerous risk stratification systems 
guide the choice on lymphadenectomy, but none is associated with a high accuracy. Lymph 
node metastases are found in 11—22% of women. If they could be accurately predicted, 
many lymphadenectomies could be avoided. The aim of this thesis was to improve 
preoperative risk assessment in women with endometrial cancer, with regard to predicting 
deep (≥ 50%) myometrial invasion (MI), cervical stromal invasion (CSI), lymph node 
metastases and recurrence or progression. 
 
Methods: All study cohorts originate from the prospective, international, multicenter IETA 
(International Endometrial Tumor Analysis) 4 ultrasound study on women with endometrial 
cancer. In Study I agreement to histopathology and interobserver reproducibility of 
subjective ultrasound assessment of MI and CSI among ultrasound experts and gynecologists 
were compared by off-line evaluation of videoclips from 53 women from a single center 
cohort. In Study II sonographic features and accuracy of ultrasound assessment of MI ≥ 50% 
were compared in tumors with and without the microcystic elongated and fragmented 
(MELF) pattern of myometrial invasion and the relationship of the MELF pattern to more 
advanced stage (≥ IB) and lymph node metastases was assessed in 850 women with 
endometrioid endometrial cancer from a multicenter cohort. In Study III a risk prediction 
model was developed on 1501 women from a multicenter cohort, to estimate the individual 
risk of lymph node metastases before surgery. In Study IV demographic, sonographic and 
Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) variables and their 
ability to predict recurrence or progression was assessed in 339 women from a single center 
cohort. 
 
Results: Gynecologists and ultrasound experts assessed MI ≥ 50% with comparable 
diagnostic accuracy and interobserver reproducibility, while ultrasound experts assessed CSI 
with greater diagnostic accuracy and interobserver reproducibility than gynecologists. 
Tumors with the MELF pattern were slightly larger, the color score was higher and the 
multiple multifocal vascular pattern was more common, compared to tumors without the 
MELF pattern. The MELF pattern did not affect the diagnostic accuracy of MI assessment, 
however it was associated with ≥ 50% MI, CSI, higher stage and lymph node metastases. A 
risk model with variables from endometrial biopsy results (histotype), clinical (age and 
bleeding duration) and ultrasound characteristics (tumor extension and tumor size) could 
reliably predict the risk of lymph node metastases before surgery, and had higher clinical 
utility than risk stratification by combined endometrial biopsy and ultrasound. Demographic 
(age ≥ 65 years and waist circumference ≥ 88 cm), sonographic (ultrasound tumor extension 
and ultrasound AP diameter ≥ 2 cm) and ProMisE variables combined had higher ability to 
predict recurrence or progression than the ESMO (European Society for Medical Oncology) 
classification. Ultrasound tumor size < 2 cm and non-p53 abnormal status identified a large 
group of women (48%) with a very low risk of tumor recurrence or progression (1.8%).  
 
Conclusion: Preoperative ultrasound staging should be performed by ultrasound experts and 
is not negatively affected by presence of the MELF status. A risk model with variables from 
endometrial biopsy, clinical and ultrasound characteristics improves preoperative risk 
prediction of lymph node metastases. Demographic, sonographic and ProMisE variables 
show the potential to predict tumor recurrence or progression already before surgery.  
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1 INTRODUCTION 
1.1 BACKGROUND 
Endometrial cancer is the most common gynecological cancer in the industrialized world, 
with approximately 1400 new cases in Sweden every year, constituting 4.5% of all cancer in 
women1. The main risk factor for developing endometrial cancer is exposure to estrogens, 
associated with obesity, early menarche, late menopause and nulliparity, as well as older age, 
the use of Tamoxifen and hereditary factors2, 3, whereas oral-contraceptive use and physical 
activity decrease the risk3. Overweight alone is responsible for around half of the cases of 
endometrial cancer in Europe and the US4.  
Due to early clinical symptoms with bleeding, endometrial cancer is often diagnosed in an 
early stage with favorable outcomes and a 5-year relative survival of 84%1. Diagnosis is 
obtained through endometrial biopsy from simple biopsy, dilatation and curettage or 
hysteroscopic resection. Established prognostic factors are FIGO (International Federation of 
Gynecology and Obstetrics) stage, histotype, FIGO grade, tumor diameter, deep myometrial 
invasion (≥ 50%), LVSI (lymphovascular space invasion), DNA ploidy, S-phase fraction, 
age, estrogen receptor (ER) and progesterone receptor (PR) expression and comorbidities2, 3, 5-
8. FIGO stage is the most important prognostic factor and reflects the 5-year survival of 90% 
for stage I, 78% for stage II, 62% for stage III and 21% for stage IV7. Within a given stage, 
those who are 80 years or older have a considerably worse prognosis, which to a certain 
degree may relate to lack of surgical staging and less aggressive adjuvant therapy7. Non-
endometrioid cancer carry a worse prognosis than endometrioid cancer and though they are 
more uncommon, they account for more than 50% of recurrences and deaths from 
endometrial cancer3. Five-year overall survival (all stages) are 85% for endometrioid tumors, 
compared with 62% for clear cell and 53% for serous cancer, with worse survival in non-
endometrioid tumors also within a given stage7. Though all considered high-risk cancers, 
serous and clear cell cancers have a significantly poorer prognosis compared with 
endometrioid cancer grade 39. Five-year overall survival in stage I endometrioid endometrial 
cancer decreases with increasing grade (grade 1: 93%, grade 2: 90% and grade 3: 79%)7. 
Tumor size and tumor extension are predictive of lymph node metastases5, 6, 10-25, recurrence 
and survival6-8, 11.  
Standard surgery in endometrial cancer is hysterectomy and bilateral salpingo-oophorectomy, 
with or without lymphadenectomy. Sentinel node biopsy has emerged as an alternative to 
lymphadenectomy, rendering staging information while reducing operation time and 
morbidity26. In the absence of sentinel node biopsy, the choice on lymphadenectomy is 
guided through preoperative risk stratification, most often based on the tentative stage, 
histotype and grade27. The prevalence of lymph node metastases in endometrial cancer is 
11—22%28-30. If the risk of lymph node metastases could be better predicted, many 
lymphadenectomies could be avoided. 
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1.2 STAGING IN ENDOMETRIAL CANCER 
The main goal of staging is to standardize management and to allow comparison of 
therapeutic strategies. The FIGO staging31 and the TNM classification32 are the staging 
systems most in use2.  
The first FIGO staging for endometrial cancer was adopted in 1950 and was clinical, meaning 
that the spread of the tumor was defined by clinical examination (Table 1). Staging was done 
after a determination of whether the cancer was confined to the corpus or had spread beyond 
it. Subdivision was performed depending on whether the woman was medically operable or 
not. However, women with clinical stage I disease where found to have tumor spread beyond 
the uterus, and an association between tumor grade, depth of myometrial invasion, extension 
to cervix and/or adnexa and the risk of lymph node metastases was demonstrated5, 33. Since 
1988 endometrial cancer is surgically staged. The major changes in the 1988 staging system 
were the use of the depth of myometrial invasion, the identification of tumor cells in 
peritoneal cytologic examination and the addition of lymph node metastases status, making 
lymphadenectomy necessary to obtain a complete surgical staging34.  
A 2017 Cochrane review35 based on two randomized controlled trials (RCT); Benedetti-
Panici et al36 and the ASTEC trial37, found no evidence that lymphadenectomy decreases the 
risk of death (overall survival: pooled hazard ratio (HZ) 1.07, 95% confidence interval (CI) 
0.81—1.43) or disease recurrence (recurrence-free survival: pooled HR 1.23, 95% CI 0.96—
1.58) compared with no lymphadenectomy, in women with presumed stage I disease (1851 
participants, two studies, moderate-quality evidence). It also concluded that women who were 
subject to lymphadenectomy were more likely to experience surgery-related systemic 
morbidity (RR 3.72, 95 % CI 1.04—13.27) or lymphedema/lymphocyst formation (RR 8.39, 
95 % CI 4.06—17.33), than those who did not undergo lymphadenectomy (1922 participants, 
two studies, high quality evidence). This has formed the rationale of not performing 
lymphadenectomy in so-called low-risk cases. The extent of surgical staging also varies 
depending on patient age, comorbidities and local practice.  
The including studies have been criticized in the retrospective SEPAL study38 for a short 
follow-up period (median 37 months, with 35.7% of surviving patients followed-up for less 
than 3 years)37, selective rather than systematic lymphadenectomy (removal of 9 or fever 
lymph nodes in 35% of women in the lymphadenectomy group)37, for not including para-
aortic lymphadenectomy36, 37 and for not assessing risk of recurrence36. The SEPAL study 
also reported a restricted survival effect of lymphadenectomy in low-risk women but a 
substantial therapeutic effect in women with intermediate- or high risk, with longer overall-, 
disease-specific- and recurrence-free survival in women subject to combined pelvic and para-
aortic lymphadenectomy compared to pelvic lymphadenectomy only38.  
No RCT evidence shows the effect of lymphadenectomy in women at high risk of recurrence 
or higher-stage disease35. 
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Table 1. Staging of endometrial cancer according to FIGO over time31,34 
Cl
in
ic
al
	st
ag
in
g	
1950	–	1961	 		
Stage	0	 Cases	which	the	pathologist	considers	most	likely	to	be	of	a	carcinomatous	nature	though	it	is	impossible	
to	arrive	at	a	definite	microscopic	diagnosis	
Stage	I	 The	growth	is	confined	to	the	uterus	
Group	1	 Operation	advisable	
Group	2	 Bad	operative	risks	
Stage	II	 The	growth	has	spread	outside	the	uterus	
1962	–	1971	 		
Stage	0	 Histological	findings	suspicious	of	malignancy	but	not	proven	
Stage	I	 The	carcinoma	is	confined	to	the	corpus	
Stage	II	 The	carcinoma	has	involved	the	corpus	and	the	cervix	
Stage	III	 The	carcinoma	has	extended	outside	the	uterus	but	not	outside	the	true	pelvis	
Stage	IV	 The	carcinoma	has	extended	outside	the	true	pelvis	or	has	obviously	involved	the	mucosa	of	the	bladder	
or	rectum	
1971	–	1988	 		
Stage	0	 Carcinoma	in-situ.	Histological	findings	suspicious	of	malignancy	
Stage	I	 The	carcinoma	is	confined	to	the	corpus	
IA	 The	length	of	the	uterine	cavity	is	8	cm	or	less	
IB	 The	length	of	the	uterine	cavity	is	greater	than	8	cm	
Stage	II	 The	carcinoma	has	involved	the	corpus	and	the	cervix	
Stage	III	 The	carcinoma	has	extended	outside	the	uterus	but	not	outside	the	true	pelvis	
Stage	IV	 The	carcinoma	has	extended	outside	the	true	pelvis	or	has	obviously	involved	the	mucosa	of	the	bladder	
or	rectum	
Su
rg
ic
al
	st
ag
in
g	
1988	–	2009	 		
Stage	I	 Tumor	limited	to	the	corpus	
IA	 Endometrium	only	
IB	 Invasion	<	50%	of	the	myometrium	
IC	 invasion	≥	50%	of	the	myometrium		
Stage	II	 Involvement	of	the	cervix	
IIA	 Cervical	glandular	invasion	only	
IIB	 Cervical	stromal	invasion	
Stage	III	 Spread	outside	of	the	uterus,	confined	to	pelvis	(not	including	bladder	or	rectal	involvement)	
IIIA	 Involvement	of	the	uterine	serosa,	adnexa	or	positive	peritoneal	cytology	
IIIB	 Spread	to	vagina	
IIIC	 Pelvic	or	para-aortic	lymph	node	metastases		
Stage	IV	 Spread	to	the	bladder,	rectum,	distant	sites	
IVA	 Involvement	of	bladder	and/or	rectal	mucosa	
IVB	 Distant,	intra-abdominal	spread,	inguinal	lymph	node	metastases	
2009	–	 		
Stage	I	 Tumor	confined	to	the	corpus	uteri	
IA	 No	or	<	50%	myometrial	invasion	
IB	 Myometrial	invasion	≥	50%			
Stage	II	 Cervical	stromal	invasion	
Stage	III	 Tumor	with	local	and/or	regional	extension	
IIIA	 Tumor	invades	the	serosa	of	the	corpus	uteri	and/or	adnexa	
IIIB	 Vaginal	and/or	parametrial	involvement	
IIIC	 Metastases	to	pelvic	and/or	para-aortic	lymph	nodes	
IIIC1	 Pelvic	lymph	node	metastases	
IIIC2	 Para-aortic	lymph	node	metastases,	with	or	without	pelvic	lymph	node	metastases	
Stage	IV	 Tumor	involving	bladder	and/or	bowel	mucosa,	and	/or	distant	metastases	
IVA	 Tumor	invasion	of	bladder	and/or	bowel	mucosa	
IVB	 Distant	disease,	including	intra-abdominal	metastases	and/or	inguinal	lymph	node	metastases	
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1.3 IMAGING IN ENDOMETRIAL CANCER 
Imaging is used in the preoperative work-up to guide primary treatment. Computed 
tomography (CT) scan or positron emission tomography (PET) scan is used to assess 
extrauterine spread, whereas transvaginal ultrasound or magnetic resonance imaging (MRI) is 
used to assess deep myometrial invasion, presence of cervical stromal invasion (CSI) and to 
rule out ovarian disease27.  
1.3.1 Ultrasound  
Preoperative ultrasound examination in women with endometrial cancer should be performed 
systematically, using a combination of transvaginal- and transabdominal ultrasound. 
Examinations should be performed with the woman in the lithotomy position with an empty 
bladder, and render information on tumor location, tumor extension and size, morphology 
and vascularization. A high-end ultrasound system should be used, with a two-dimensional or 
three-dimensional 3—5 to 9—10 MHz transvaginal transducer and a convex array abdominal 
probe (3.5—7 MHz). The transvaginal approach is optimal for examination of the uterus. If 
transvaginal examination cannot be performed, the probe can be inserted transrectally. 
Scanning of the uterus should be performed in the sagittal plane, from cornu to cornu, and in 
the transverse plane, from the cervix to the fundus, to establish an overview.  
In order to assess cervical stromal invasion the ultrasound image should be magnified in the 
sagittal plane to contain only the cervix uteri. The level of entry of the uterine arteries 
corresponds approximately to the internal cervical os. The assessment of stromal invasion can 
be aided by the application of pressure with the transvaginal probe, to see if the tumor slides 
against the endocervical mucosa. In the case of gross cervical invasion, parametrial invasion 
should be assessed. If the tumor has its greatest dimensions in the isthmus region, it can be 
difficult to determine if the primarity of the tumor is the endometrium or the cervix, and tru-
cut biopsy can be diagnostic.  
After the cervix has been assessed, the whole uterine body should be visualized, with 
magnification of the image in the sagittal plane to contain only the uterine corpus. Scanning 
should be performed in the sagittal plane, from cornu to cornu, and in the transverse plane, 
from the cervix to the fundus, with description of myometrial invasion and endometrial 
morphology using grayscale ultrasound, and of vascularization using color and power 
Doppler. When using color and power Doppler, the Doppler box should include the 
endometrium and the surrounding myometrium and the settings should be adjusted to an 
ultrasound frequency of at least 5 MHz, pulse repetition frequency 0.3—0.9 kHz, and 
reduction of the power Doppler gain until all color artifacts disappear.  
Extrauterine tumor extension should be described, using both transvaginal- and 
transabdominal ultrasound39-41.  
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Figure 1. Ultrasound tumor measurements: a) the distance from the lower margin of the tumor to the 
outer cervical os in the sagittal plane, b) the anteroposterior (AP) uterine diameter, the AP tumor 
diameter (tumor thickness) and the craniocaudal tumor diameter (tumor length) in the sagittal plane, 
c) laterolateral uterine diameter (uterine width) and laterolateral tumor diameter (tumor width) in the 
transverse plane and d) minimal tumor-free margin to the serosa, measurable in any plane. Reprinted 
with permision66 
 
1.3.1.1 Staging 
Deep myometrial invasion can be evaluated using subjective assessment, by estimating the 
proportion of tumor invasion in relationship to the normal myometrial wall thickness (< 50% 
or ≥ 50%) (Figure 2), or by measurement techniques, such as the deepest invasion/normal 
myometrium ratio (Gordon's ratio)42, tumor/uterine anteroposterior (AP) diameter ratio, 
(Karlsson's ratio)43, endometrial thickness44, tumor/uterine volume ratio44, minimal tumor-
free margin/uterine AP diameter ratio44 and the shortest distance to serosa45 (Figure 1).  
Cervical stromal invasion can be evaluated using subjective assessment (Figure 2) or by 
measurement techniques, measuring the distance from the lower margin of the tumor to the 
outer cervical os44 (Figure 1).  
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Figure 2. Ultrasound tumor extension: a) myometrial invasion < 50%, b) myometrial invasion ≥ 50%, 
c) no cervical stromal invasion, d) cervical stromal invasion. 
 
Subjective assessment of deep myometrial invasion and cervical stromal invasion performs 
better than measurement techniques and is associated with sensitivities and specificities 
ranging from 61%—93% vs. 71%—90%, respectively, for deep myometrial invasion44-56 and 
29%—93% vs. 85%—99%, respectively, for cervical stromal invasion44, 48, 52, 55-62 (Table 2). 
The accuracy of subjective assessment of deep myometrial invasion and cervical stromal 
invasion is affected by tumor size and tumor vascularity, with increased risk of 
underestimation in tumors with lower volume, lesser endometrial thickness, thicker minimum 
tumor-free myometrium and lower color score (1—2) and increased risk of overestimation in 
tumors with higher volume, greater endometrial thickness, lesser minimum tumor-free 
myometrium and higher color score (3—4). BMI, uterine position and image quality has not 
been shown to affect the risk of staging error63.  
The adnexal region should be assessed, to rule out ovarian spread or synchronous ovarian 
cancer, reported to occur in 5% of cases64. Ultrasound-guided tru-cut biopsy can be used to 
establish tumor primarity in most cases. Adnexal metastases can be diagnosed by ultrasound 
with a sensitivity of 73% and a specificity of 98%, whereas assessment of pelvic lymph node 
metastases is associated with poor sensitivity (sensitivity 33% and specificity 100%)58.  
  
a b 
d c  
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Table 2. Subjective assessment of deep myometrial invasion (≥ 50%) and cervical stromal invasion 
by transvaginal ultrasound 
      Deep myometrial invasion   Cervical stromal invasion 
  Year N= Sensitivity (%) Specificity (%)   Sensitivity (%) Specificity (%) 
Gabrielli et al. 1996 67 — —   54 87 
van Doorn et al. 2002 93 79 72   — — 
Sawicki et al. 2003 90 — —   86 85 
De Smet et al. 2006 97 61 86   — — 
Savelli et al. 2008 74 84 83   93 92 
Alcazar et al. 2009 96 93 82   — — 
Ozdemir et al. 2009 64 85 75   — — 
Celik et al. 2010 64 — —   88 92 
Akbayir et al. 2011 298 — —   77 99 
Akbayir et al. 2012 219 62 81   — — 
Savelli et al. 2012 155 75 89   — — 
Antonsen et al. 2013 195 71 72   29 92 
Mascilini et al. 2013 144 77 81   54 93 
Ortoft et al. 2013 156 — —   38 89 
Van Holsbeke 2014 211 83 71   — — 
Alcazar et al. 2015 169 80 90   — — 
Christensen et al. 2016 110 — —   39 88 
Frühauf et al. 2017 210 79 73   41 94 
Verbakel et al. 2019 1538 70 80   49 94 
 
1.3.1.2 Endometrial morphology 
Assessment of endometrial morphology according to IETA (International Endometrial Tumor 
Analysis) includes description of echogenicity, the endometrial midline, bright edge and the 
endometrial-myometrial junction40.  
The echogenicity of the endometrium is compared with the echogenicity of the myometrium, 
and described as "uniform", if the endometrium is homogenous and symmetrical (Figure 3) or 
"non-uniform", if the endometrium is heterogeneous, asymmetrical or cystic (Figure 4). The 
endometrial midline is described as "linear" or "non-linear", if a hyperechogenic interface 
within the endometrium is visualized, and "irregular" or "not defined", in the absence of a 
distinct interface (Figure 5). If an echo is formed by the interface between an intracavitary 
lesion and the endometrium it is called the "bright edge" (Figure 6). The border between the 
endometrium and myometrium, called the endometrial-myometrial junction, is described as 
"regular", "irregular", "interrupted" or "not defined" (Figure 7).  
On ultrasound, non-uniform echogenicity and a non-regular endometrial-myometrial junction 
are associated with higher grade, higher stage and high-risk cancer65, 66. 
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Figure 3. Uniform echogenicity: a) three-layer pattern, b) hypoechogenic, c) hyperechogenic and d) 
isoechogenic. Reprinted with permission40 
 
 
 
 
Figure 4. Non-uniform echogenicity: a) homogeneous background with regular cystic areas, b) 
homogenous background without irregular cystic areas, c) heterogeneous background without cystic 
areas, d) heterogeneous background with regular cystic areas and e) heterogeneous background with 
irregular cystic areas. Reprinted with permission40 
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Figure 5. Endometrial midline: a) linear, b) non-linear, c) irregular and d) not defined. Reprinted 
with permission40 
 
 
Figure 6. Bright edge. Reprinted with permission40 
 
 
Figure 7. Endometrial-myometrial junction: a) regular, b) irregular, c) interrupted and d) not 
defined. Reprinted with permission40 
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1.3.1.3 Color score and vascular Morphology using power Doppler 
The color score is a subjective semi quantitative assessment of the amount of blood flow 
present in the endometrium, and may be scored using the International Ovarian Tumor 
Analysis (IOTA) color score for ovarian masses67. The color flow reflects the blood flow, 
resulting in a color score from 1—440 (Figure 8). The vascular pattern describes the 
distribution of vessels within the endometrium, and is reported with respect to the presence or 
absence of dominant vessels or other specific patterns40. Focus is put on the number of 
vessels (single or multiple) and the myometrial-endometrial junction origin of the vessels 
(focal, multifocal or not visible) (Figure 9). On ultrasound, multiple vessels of focal or 
multifocal origin and a higher color score are associated with endometrioid grade 3 or non-
endometrioid tumors, larger tumor size, higher stage and high-risk cancer65, 66. 
 
Figure 8. Color score: a) color score 1: no color flow, b) color score 2: minimal color flow, c) color 
score 3: moderate color flow, d) color score 4: abundant color flow. Reprinted with permission40 
 
Figure 9. Vascular pattern: a) single dominant vessel without branching, b) single dominant vessel 
with branching, c) multiple vessels with focal origin, d) multiple vessels with multifocal origin, e) 
scattered vessels and f) circular flow. Reprinted with permission40 
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1.3.1.4 Tumor size 
The size of the tumor is measured using three perpendicular diameters; tumor AP diameter 
(when the tumor is defined) or endometrial thickness (when the tumor is not defined) in the 
sagittal plane, longitudinal diameter in the sagittal plane and tumor lateral diameter in the 
transverse plane. The relative tumor size is measured through the AP tumor/uterine diameter 
ratio. The tumor volume is obtained either from 2D ultrasound using the approximate formula 
for an ellipsoid,	 ((AP	 diameter	 ×	 length	 ×	 width)	 /	 2)66 or from 3D ultrasound 
measurement68 (Figure 1).  
Increased tumor size, as measured by tumor volume or endometrial thickness, is associated 
with deep myometrial invasion, non-endometrioid cancer, higher grade, higher stage, lymph 
node metastases and high-risk cancer66, 69. 
1.3.1.5 Three-dimensional (3D) ultrasound 
Three-dimensional ultrasound enables rapid acquisition of ultrasound images, with the ability 
to display volume-rendered images of the uterine corpus and the cervix. Three-dimensional 
ultrasound allows virtual navigation through multiplanar display, with off-line analysis in any 
plane, including the reconstructed coronal plane, and surface rendering, i.e. the reconstruction 
of the outline and the internal contour of the uterus.  
Three-dimensional ultrasound enables calculation of vascular indexes (vascularization index, 
flow index and vascularization-flow index), a 3D reconstruction of the vascular tree and the 
calculation of tumor volumes even in irregularly shaped structures. In 3D ultrasound, the 
volume contrast imaging technique projects a 1-10 mm slice of a volume dataset onto a two-
dimensional (2D) screen. The obtained image has an enhanced tissue demarcation, due to the 
filling of gaps in the image by tissue information from adjacent layers.  
Due to computer generation, 3D ultrasound is sensitive to motion artifacts and pre-acquisition 
image quality and requires more user input than 2D imaging, as data must be manipulated 
after being obtained. An inappropriate technique when manipulating data can result in the 
creation of artifacts68, 70.  
Three-dimensional ultrasound has been associated with reliable assessment of myometrial 
invasion45 but has not proved superior to 2D ultrasound62 or MRI62, 71, 72 in the assessment of 
deep myometrial invasion62, 71, 72 or cervical stromal invasion71.  
1.3.1.6 Ultrasound appearance of endometrial cancer 
Grayscale and color power Doppler sonographic features in endometrial cancer vary with 
histotype, stage and grade. With increasing stage and grade, tumors are larger, have higher 
color score and are less likely to have regular endometrial-myometrial junction or uniform 
echogenicity. Non-endometrioid tumors are generally larger than endometrioid tumors, with a 
vascularity similar to that of high-grade (grade 3) endometrioid tumors but a morphology 
similar to that of low-grade (grade 1—2) endometrioid tumors.  
 12 
Compared to low-grade tumors and low-risk tumors (low-grade endometrioid cancer stage 
IA), high-grade tumors and high-risk tumors (endometrioid cancer grade 3, non-endometrioid 
cancer or stage ≥IB) have greater size, as measured by endometrial thickness and tumor 
volume, are less likely to have uniform echogenicity or regular endometrial-myometrial 
junction and more likely to have multiple vessels of focal or multifocal origin and a higher 
color score66 (Figure 10).  
 
 
Figure 10. Tumor ultrasound appearance depending on risk: a) low-risk tumor, b) high-risk tumor. 
 
1.3.1.7  Strengths and limitations of ultrasound 
Ultrasound poses the advantages of wide availability, low cost, short examination time, no 
ionizing radiation and no need for intravenous contrast, but requires a skilled examiner with a 
high constant rate of examinations to maintain skill. The possibility to assess the 
endometrium by transvaginal ultrasound is limited if the uterus is in the upright position, 
which may be the case in obese women due to excess intra-abdominal fat39. In these cases, 
the addition of transabdominal or even transrectal ultrasound may give additional 
information. Still, in the minority of cases image-quality is too poor to delineate the tumor 
using ultrasound, and MRI is an alternative, unless there are contraindications to MRI as well. 
1.3.2 MRI 
Meta-analyzes on assessment of deep myometrial invasion73-76 and cervical stromal 
invasion75, 76 by MRI report sensitivities and specificities ranging from 79%—90% vs. 
81%—95% for deep myometrial invasion and 50%—57% vs. 95% for cervical stromal 
invasion.  
Publications comparing ultrasound and MRI in the same set of women show similar results 
regarding the assessment of deep myometrial invasion48, 49, 52 and cervical stromal invasion48, 
52, 59, 61, 62, 77 (Table 3). In accordance to ultrasound, MRI has a low sensitivity for the 
prediction of lymph node metastases (sensitivity 59% and specificity 95%)76. 
a b 
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Table 3. Comparison of transvaginal ultrasound and magnetic resonance imaging (MRI) in the 
subjective assessment of deep myometrial invasion (≥ 50%) and cervical stromal invasion in the same 
set of women 
a. Deep myometrial invasion 
      Ultrasound MRI 
  Year N= Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Cicinelli et al 2008 100 — — — — 
Savelli et al 2008 74 84 83 84 81 
Ozdemir et al 2009 64 85 75 85 79 
Celik et al 2010 64 — — — — 
Antonsen et al 2013 123 69 74 89 57 
Ortoft et al 2013 156 — — — — 
Christensen et al 2016 110 — — — — 
	 	 	 	 	 	 	b.Cervical stromal invasion 
	 	 	 	
      Ultrasound MRI 
  Year N= Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Cicinelli et al 2008 100 53 82 67 95 
Savelli et al 2008 74 93 92 79 87 
Ozdemir et al 2009 64 — — — — 
Celik et al 2010 64 88 92 88 94 
Antonsen et al 2013 123 19 94 27 94 
Ortoft et al 2013 156 38 89 54 91 
Christensen et al 2016 110 39 88 56 90 
 
1.4 HISTOPATHOLOGY IN ENDOMETRIAL CANCER 
Histopathological assessment plays a central role in endometrial cancer, by classifying the 
tumor and by staging it. Endometrial cancer is classified on the basis of tumor cell type and, 
in the case of endometrioid cancer, also by grade78. 
1.4.1 Cell type 
Endometrial cancers are classified as endometrioid (80—90%) or non-endometrioid (10—
20%), including various subtypes such as serous, clear-cell, undifferentiated carcinoma or 
carcinosarcoma27. Assessment of cell type is made on the basis of histological criteria on 
hematoxylin and eosin (H&E) stain and is critical, as it determines the extent of surgery and 
the use of adjuvant therapy. The main categories are the endometrioid adenocarcinoma, 
which contains glands resembling those of the normal endometrium, and is often found on a 
background of atypical hyperplasia, the serous carcinoma, which is characterized by a 
complex pattern of papillae with cellular budding, and is often found on a background of 
atrophical endometrium, the clear cell adenocarcinoma, which is composed mainly of clear 
and hobnail cells, in solid tubulocystic or papillary patterns and the undifferentiated 
carcinomas, which lack any evidence of differentiation. Also, mixed tumors are common. 
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Sometimes, differential diagnostics for cell type can be difficult, for instance between 
endometrioid and serous carcinoma. Immunohistochemistry can be used as a diagnostic aid, 
based on immunophenotypic differences between cell types. A panel of immunomarkers, 
containing p53, estrogen receptor (ER), phosphatase and tensin homologue (PTEN) and p16 
are often used to distinguish endometrioid (p53 negative, ER positive, PTEN negative, p16 
negative) from serous carcinoma (p53 positive, ER negative, PTEN positive, p16 positive). 
Interpretative difficulties remain in cases with intermediate immunostaining results78. 
1.4.2 Grade 
According to the 1988 FIGO three-tire grading system, the tumor is graded based on the 
percentage of solid non-squamous growth; grade 1: ≤ 5% solid growth; grade 2: 6—50% 
solid growth; grade 3: > 50% solid growth. If there is notable nuclear atypia in grade 1 or 
grade 2 tumors, the grade is increased by one78, 79.  
Problems with the FIGO grading are difficulties in distinction between solid growth and areas 
of immature squamous metaplasia or compressed confluent glands, quantification of the 
percentage of solid growth near cut-off points between grades and lacking morphological and 
morphometric criteria on notable nuclear atypia. These interpretive difficulties confer a 
limited interobserver reproducibility for grade. Also, cut-offs between grades have been 
arbitrary set, and not driven based on outcome78.  
Two-tired (binary) grading systems have been suggested80-83, to improve reproducibility and 
to make grading more compatible with treatment options with two alternatives, such as to 
perform lymphadenectomy or not and to give adjuvant treatment or not. In contrast to the 
two-tired grading system in serous carcinoma of the ovary, where there are fundamental 
differences, including molecular differences (p53 and Ki-67), between low- and high grade, 
endometrioid endometrial cancer exhibits a continuum between low- and high grade, without 
any reliable molecular markers to aid in the development of a binary grading system78.  
1.4.3 Stage 
The surgical specimen is assessed regarding the depth of myometrial invasion (< 50% vs. ≥ 
50%), the presence of cervical stromal invasion (no vs. yes) and extrauterine spread (no vs. 
yes, as well as location of spread, if present), to determine the surgical stage according to the 
FIGO 2009 staging system31.  
The depth of myometrial invasion is measured at the point of deepest invasion and affects 
tumor stage. Instead of conventional myometrial invasion, a subset of endometrioid 
endometrial cancers exhibit the microcystic elongated and fragmented (MELF) pattern of 
myometrial invasion78. The MELF pattern shows distinctive morphologic alterations, with 
detached neoplastic glands, appearing either as microcysts (M), elongated structures (EL) or 
fragmented small solid clusters or single cells (F)84 and can be found in 7—48% of 
endometrioid endometrial cancer84-92 (Figure 11). Separation of epithelial formations from the 
superficial, more easily identified tumor from which they originated can lead to an 
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underestimation of the deepest extent of myometrial invasion, with subsequent tumor 
understaging 84-87, 92. In addition, the MELF pattern has been suggested to represent a more 
aggressive variant of endometrioid endometrial cancer, as it has been associated with lymph 
node metastases 85-90, 93 and an increased risk of recurrence 94.  
 
 
Figure 11. The microcystic elongated and fragmented (MELF) pattern of myometrial invasion, on  
a) histopathology and b) ultrasound. 
 
1.5 INTEROBSERVER REPRODUCIBILITY IN ENDOMETRIAL CANCER 
High interobserver agreement or reproducibility, i.e. how well different assessors agree on the 
interpretation, is crucial for the usefulness of a diagnostic test. 
1.5.1 Ultrasound 
When study I was designed, published interobserver reproducibility studies on ultrasound in 
endometrial cancer were limited to 3D ultrasound in relation to endometrial volume and 
vascularity measurements95 and there were no publications on interobserver reproducibility in 
ultrasound staging.  
1.5.2 MRI 
Interobserver reproducibility in MRI staging (1.5 T MRI) has been reported to be fair to good 
for deep myometrial invasion (kappa (κ) 0.32—0.67) and moderate to good for cervical 
stromal invasion (κ 0.50—0.76) and lymph node metastases (κ 0.54—0.74)96-98.  
1.5.3 Histopathology 
Interobserver reproducibility in histopathological staging has been reported to be good to 
very good for deep myometrial invasion (κ 0.75—0.84) and moderate for cervical stromal 
invasion (κ 0.49)99-101 
Tumor histotype and grade have limited interobserver reproducibility (κ 0.62—0.87 vs. 
0.35—0.65, respectively)78, 102, especially in high-grade tumors, as defined by grade 3 
endometrioid cancer or non-endometrioid cancer103, 104. Binary grading systems have been 
b a 
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associated with higher interobserver reproducibility than the three-tire FIGO grading 
system80, 81, 83, 102, 105, 106. Converting the three-tire FIGO grading system into a two-tire 
grading system by combining grade 1 and 2 has been associated with prognostic significance 
for locoregional and distant recurrence and disease-specific survival and to be associated with 
a higher interobserver reproducibility78, 82, 83, 106.  
A meta-analysis from 2017 (45 studies, 12 459 women) on agreement between preoperative 
biopsy and final histology according to the hysterectomy specimen reported a pooled 
agreement of 67% for grade, with the lowest agreement in preoperative grade 2 cancer (61%). 
Agreement on histologic subtype was 95% for endometrioid cancer and 81% for non-
endometrioid cancer. Authors concluded that overall, agreement on tumor grade between 
preoperative biopsy and the hysterectomy specimen was only moderate107.  
Histopathologic morphology assessment has been reported to only identify two different 
prognostic groups reproducibly, i.e. high-grade and low-grade tumors, and authors concluded 
that a more refined risk assessment in endometrial cancer requires the use of molecular 
markers106. 
1.6 MOLECULAR MARKERS IN ENDOMETRIAL CANCER 
Several molecular markers have been identified for endometrial cancer, constituting hormone 
receptors, DNA ploidy, oncogenes, cancer suppressor genes, mismatch repair genes, 
apoptosis-associated genes and indicators of cell proliferation108. Molecular markers offer the 
advantage of objective results, as they are based on the presence or the absence of a protein or 
mutation. They have been used in endometrial cancer to improve sub classification109-115, to 
detect prognostic subgroups116-122, in risk prediction models123-126 and in individualized 
therapy127.  
Historically, endometrial cancer was classified into two pathogenic types: type I, comprising 
endometrioid endometrial cancer associated with good prognosis and type II, comprising 
non-endometrioid endometrial cancer associated with a higher risk of metastases and poor 
prognosis128. Molecular data have supported this dichotomous classification, with genetic 
alterations in PTEN, KRAS2, CTNNB1 and PIK3CA and LMH1 promoter hypermethylation 
in type I cancer27 and mutations in p53 and HER-2/neu in type II cancer3. However, 
considerable molecular heterogeneity exists, with expression of p53 mutations in 25% of 
endometrioid grade 3 cancer129. Also, its prognostic value is limited, as 20% of type I cancer 
relapse, whereas 50% of type II cancers do not2.  
The Cancer Genome Atlas (TCGA) Research Network developed a genomic classification of 
endometrial cancer into four prognostic subgroups: POLE ultramutated, microsatellite 
instability hypermutated (MSI), copy-number low (CN low) and copy-number high (CN 
high)129. The TCGA classification is associated with complex and costly methodologies, and 
the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) was developed 
and validated as a clinically applicable surrogate molecular classification system130-133. It is 
based on a combination of mutation and protein expression analysis and renders four distinct 
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prognostic subgroups: polymerase-ε exonuclease domain mutations (POLE EDM), mismatch 
repair proteins deficiency (MMR-D), protein 53 wild type (p53 wt) and protein 53 abnormal 
(p53 abn). The level of consensus of histotype and grade assessment has been shown to vary 
with ProMisE subtype (p53 wt: 90%, POLE EDM: 65%, MMR-D: 58% and p53 abn: 
39%)134 and compared to histotype and grade, ProMisE is associated with a higher agreement 
between preoperative biopsy and hysterectomy specimen133, 135, 136.  
1.7 RISK ASSESSMENT IN ENDOMETRIAL CANCER 
There is no universal definition of "low risk" and "high risk" in endometrial cancer. 
Numerous risk stratification systems are used for classifying the risk of lymph node 
metastases and recurrence2, 137, 138, such as the Mayo criteria6, PORTEC-1139 (Post Operative 
Radiation Therapy in Endometrial Carcinoma), GOG-99140 (Gyneacologic Oncology Group 
adjuvant radiation for intermediate-risk endometrial cancers), SEPAL38 (Survival Effect of 
Para-Aortic Lymphadenectomy in endometrial cancer), ESMO classification141 (European 
Society of Medical Oncology), ESMO modified classification142 and Mayo-modified 
criteria143 (Table 4). When compared, the ESMO modified classification most accurately 
predicted lymph node metastases138, 144 and risk of recurrence144.  
Published preoperative risk models in endometrial cancer predict the risk of lymph node 
metastases25, 145-149 (Table 5), postoperative high risk53, 61, 123 and advanced stage150, with25, 53, 
61, 145-149 or without123, 150 the use of imaging. Some preoperative risk models for lymph node 
metastases145-147 have been subject to external validation, limited by selective cohorts and 
missing data, due to the retrospective nature of the studies151, 152. Comparison of model 
performance is difficult, as long as the models are not validated on the same identical 
validation cohort, representative to the target population for the model. Tumor histotype and 
grade have limited interobserver reproducibility78, 102-104 and agreement on tumor grade 
between preoperative biopsy and the hysterectomy specimen is only moderate107, limiting 
their use in preoperative risk classification. Possibly could molecular classification systems 
allow more objective results, as they are based on the presence or the absence of a protein or 
a mutation. Integration of histopathologic and molecular factors has been shown to improve 
risk assessment in women with early-stage endometrial cancer120. 
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 Table 4. Classification systems used in endometrial cancer 
Classification	 Year	 N	=	 Variables	
	 	 	 	
Mayo	criteria6	 2000	 328	 Histotype	(endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(no	vs.	≤	50%	vs.	>	50%)	
	 	 	 Primary	tumor	diameter	(≤	2	cm	vs.	>	2	cm)	
	 	 	 	
PORTEC-1139	 2000	 715	 Age	
	 	 	 Histotype	(endometrioid	vs.	non-endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(<	50%	vs.	≥	50%)	
	 	 	 	
GOG-99140	 2004	 392	 Age	
	 	 	 Histologic	type	(endometrioid	vs.	non-endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(<	outer	1/3	vs.	≥	outer	1/3)		
	 	 	 FIGO	stage	
	 	 	 LVSI	
	 	 	 	
SEPAL38	 2010	 671	 Histologic	type	(endometrioid	vs.	non-endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 FIGO	stage	
	 	 	 LVSI	
	 	 	 	
ESMO141	 2013	 —	 Histologic	type	(endometrioid	vs.	non-endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(<	50%	vs.	≥	50%)	
	 	 	 	
ESMO	modified142	 2014	 496	 Histologic	type	(endometrioid	vs.	non-endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(<	50%	vs.	≥	50%)	
	 	 	 LVSI	
	 	 	 	
Mayo-modified	criteria143	 2014	 19	329	 Histotype	(endometrioid)	
	 	 	 FIGO	grade	(1	vs.	2	vs.	3)	
	 	 	 Myometrial	invasion	(no	vs.	<	50%	vs.	≥	50%)	
		 		 		 Primary	tumor	diameter	(≤	3	cm	vs.	>	3	cm)	
ESMO: European Society of Medical Oncology; FIGO: International Federation of Gynecology and 
Obstetrics; GOG: Gynecologic Oncology Group; LVSI: lymphovascular space invasion; PORTEC: 
Post Operative Radiation Therapy in Endometrial Carcinoma; SEPAL: Survival Effect of Para-Aortic 
Lymphadenectomy in Endometrial Cancer 
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Table 5. Published preoperative risk prediction models for lymph node metastases 
  Year N = Cohort  Histotype Staging Imaging Predictors 
Todo145 2003 214 Retrospective 
Multicenter 
Treatment 
between 
1993—2000 
Endometrioid 
and non-
endometrioid 
FIGO 1988 
Stage I—IV 
MRI Pelvic lymph node metastases:  
Serous histotype (yes vs. no)  
Volume index (< 25 vs. ≥ 25)  
Grade (1—2 vs. 3)  
CA 125 (< 70 vs. ≥ 70 if age <50 years 
and < 28 vs. ≥ 28 if age ≥ 50 years)  
Para-aortic lymph node metastases 
Volume index (< 40 vs.  ≥ 40)  
CA 125 (< 70 vs.  ≥ 70 if age < 50 
years and < 28 vs. ≥ 28 if age ≥ 50 
years) 
            
Lee146  2010 110 Retrospective 
Presumed one 
center 
Treatment 
between 
2001—2008 
Endometrioid 
and non-
endometrioid 
FIGO 1988 
Stage I—IV 
MRI CA 125 (< 70 vs. ≥ 70)  
Any MI (yes/no)  
Grade (1 vs. 2—3)  
Extension beyond uterus (yes vs. no) 
            
Kang147 2012 360 Retrospective 
Multicenter 
Treatment 
between 
2002—2008 
Endometrioid FIGO 1988 
Stage I—IV 
MRI CA 125 (< 35 vs. ≥ 35)  
MI (< 50% vs. ≥ 50%)  
Extension beyond corpus (yes vs. no) 
Enlarged lymph nodes (yes vs. no) 
             
Koskas148* 2014 181 Retrospective 
Multicenter 
Treatment 
between 
2000—2010 
Endometrioid 
and non-
endometrioid 
Presumed 
FIGO 2009 
Tentative 
stage I—II 
MRI Age (years) 
Race (white vs. black vs. others)  
Subtype (adenocarcinoma vs. papillary 
serous vs. clear cell vs. 
carcinosarcoma)  
Grade (1 vs. 2 vs. 3)  
Spread (no MI vs. MI < 50% vs. MI ≥ 
50% vs. CSI) 
            
Son149 2015 142 Retrospective 
One center 
Treatment 
between 
2000—2013 
Endometrioid 
grade 1—2 
Presumed 
FIGO 2009 
Tentative 
Stage IA 
MRI Grade 1 and CA 125 < 35 vs.  
grade 2 or CA 125 ≥ 35 
             
Lee25 2016 172 Retrospective 
Presumed one 
center 
Treatment 
between 
2000—2013 
Endometrioid 
and non-
endometrioid 
FIGO 2009 
Stage I—IV 
TVS MI (< 50% vs. ≥ 50%)  
Grade (1 vs. 2—3)  
CA 125 (< 35 vs. ≥ 35) 
CSI: cervical stromal invasion; MI: myometrial invasion; MRI: magnetic resonance imaging; TVS: 
transvaginal ultrasound 
* The nomogram by Bendifallah et al14 used on preoperative variables 
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1.8 SUMMARY 
There is a need for improved preoperative risk assessment, to avoid under- or over treatment 
in terms of lymphadenectomy. Gynecologists use ultrasound in their everyday work. If they 
could assess deep myometrial invasion and cervical stromal invasion as good as ultrasound 
experts, that would aid in the triage of high-risk endometrial cancer, for referral to tertiary 
centers for surgery with lymphadenectomy.  
The MELF pattern could constitute an adverse factor in endometrioid endometrial cancer and 
could be a reason for underestimating myometrial invasion, not only in histopathology but 
also in preoperative ultrasound staging.  
Published preoperative risk prediction models for lymph node metastases are based on 
relatively small, retrospective cohorts, and the majority use MRI for imaging. The IETA 4 
cohort66 would enable model building on a large, multicenter, prospective cohort with high 
quality ultrasound data.  
ProMisE poses the advantage over histotype and grade of higher agreement between biopsy 
and hysterectomy specimen133, 135, 136, making it suitable for preoperative risk prediction. 
Possibly could ProMisE, demographic- and sonographic variables predict recurrence or 
progression already before surgery. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to improve preoperative risk assessment in women with 
endometrial cancer. 
The specific aims were: 
Study I 
To assess interobserver reproducibility among ultrasound experts and gynecologists in the 
prediction of deep myometrial invasion and cervical stromal invasion by transvaginal 
ultrasound.  
Study II 
To describe sonographic features of the microcystic elongated and fragmented (MELF) 
pattern of myometrial invasion, to assess the effect of the MELF pattern on evaluation of 
myometrial invasion and to explore the relationship of the MELF pattern to more advanced 
stage (≥IB) and lymph node metastases.  
Study III 
To develop a preoperative risk prediction model on a large prospective cohort with variables 
from demography, endometrial biopsy and ultrasound, to estimate the individual risk of 
lymph node metastases. 
Study IV 
To assess demographic, sonographic and Proactive Molecular Risk Classifier for Endometrial 
Cancer (ProMisE) variables, and their ability to predict recurrence or progression before 
surgery. 
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3 PARTICIPANTS AND METHODS 
All study cohorts originate from the prospective, international, multicenter IETA 4 study66 on 
women with endometrial cancer, examined preoperatively with ultrasound according to the 
IETA study protocol40 (Figure 12).  
 
 
Figure 12. Flowchart of the study populations. 
Women were recruited to the IETA 4 study between 1 January 2011 and 31 December 2015, 
from 17 European centers in 7 countries. Inclusion criteria were endometrial cancer according 
to preoperative biopsy or suspicion of cancer according to ultrasound, in the case of missing 
biopsy or biopsy without confirmed cancer (i.e. hyperplasia). Exclusion criteria were 
hysterectomy; not performed, carried out at another hospital or performed later than 120 days 
after ultrasound examination, final diagnosis other than endometrial cancer, incomplete data 
on ultrasound, duplicate entries and error in the identification key.  
Ultrasound data was obtained by experienced ultrasound examiners, using high-end 
ultrasound equipment and following the IETA examination technique and terminology, 
previously described40. The IETA protocol included subjective assessment of the presence of 
deep myometrial invasion and cervical stromal invasion, measurements of maximum 
endometrial thickness and uterine AP diameter (sagittal section), uterine width (transverse 
Inclusions 
n = 1714 
  
Study III 
n = 1501 
	 
Stockholm cohort 
n = 409 	  IETA cohort n = 1538 
  
IETA cohort 
n = 1538 
	 
Study IV 
n = 339 
Hysterectomy; not performed, performed at another hospital 
or ≥ 120 days after ultrasound, n = 118 
Diagnos other than endometrial cancer, n = 25 
Missing ultrasound data due to incorrect fillout of the study 
protocol, n = 26 
Duplicate entries, n = 5 
Error in the identification key, n = 2 
US between June 
2011 and Oct 2012 
and complete 
videoclips 
n = 55 
	 
Study I 
n = 53 
No remaining 
cancer, n = 1 
Technical reasons, 
n = 1 
	 
Study II 
n = 850 
No MELF 
analysis,  
n = 20 
	 
IETA cohort 
n = 1538 
Screening 
population, 
n = 37 
Surgery performed in another 
hospital, n = 6 
Too little or no remaining tumor, 
n = 38 
Incorrect personal security 
number, n = 2 
Incomplete ProMisE analysis, 
n = 8 
Duplicate case, n = 1 
Technical reasons, n = 17 
  
	 
Stockholm cohort 
n = 409 
Endometrioid cancer 
from 8/9 centra with  
≥ 50 inclusions, 
n = 870 
n = 870 
+2 added 
  23 
section), three maximum orthogonal tumor diameters; AP diameter and length (sagittal plane) 
and width (transverse plane), minimal tumor-free margin (in the plane where the distance 
from the tumor to the serosa appeared to be smallest), distance from the lower margin of the 
tumor to the outer cervical os (sagittal plane) and tumor volume (calculated from the three 
orthogonal tumor diameters using the approximate formula for an ellipsoid ((AP-diameter x 
length x width) /2) (Figure 1).  
All women were subject to hysterectomy and bilateral salpingo-oophorectomy, with or 
without lymphadenectomy depending on local protocols. Tumors were staged according to 
the FIGO 2009 staging criteria31 and grade was classified according to FIGO79.  
Data on demography and ultrasound variables were entered into an internet-based data 
capture software, Clinical Data Miner (https://cdm.esat.kuleuven.be)153 before surgery and 
data on histopathology and surgical stage were entered following surgery. Incomplete forms 
could not be saved, which assured completeness of records. Once saved, data was locked to 
changes. The demographic data of the study cohorts is presented in Table 6. 
 
Table 6. Demographic data on the study populations 
		 		 Study	1	 Study	2	 Study	3	 Study	4	
Number	of	women	 53	 850	 1501	 339	
Age	(years)	 72	(62—77)	 65	(58—72)	 65	(59—72)	 67	(60—72)	
Body	Mass	Index	(kg/m2)	 28	(24—34)	 29	(24—34)	 28	(24—33)	 27	(24—33)	
Histotype	and	grade*	 	 	 	 	
		 Endometrioid	grade	1	 16	(30)	 295	(35)	 572	(38)	 141	(42)	
		 Endometrioid	grade	2	 23	(43)	 408	(48)	 490	(33)	 103	(30)	
		 Endometrioid	grade	3	 9	(17)	 147	(17)	 210	(14)	 46	(14)	
		 Non-endometrioid	 5	(9)	 —	 198	(13)	 49	(14)	
		 No	remaining	tumor	 —	 —	 31	(2)	 —	
Stage	FIGO	2009	 	 	 	 	
		 IA	 34	(64)	 527	(62)	 904	(60)	 205	(60)	
		 IB	 9	(17)	 192	(23)	 321	(21)	 72	(21)	
		 II	 6	(11)	 51	(6)	 86	(6)	 28	(8)	
		 III	 3	(6)	 75	(9)	 168	(11)	 24	(7)	
		 IV	 1	(2)	 5	(0.6)	 22	(1.5)	 10	(3)	
Deep	myometrial	invasion	 19	(36)	 286	(34)	 565	(38)	 113	(33)	
Cervical	stromal	invasion		 9	(17)	 76	(9)	 158	(11)	 41	(12)	
Results are presented as median (IQR) or n (%) 
*hysterectomy specimen 
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3.1 PARTICIPANTS 
3.1.1 Study I 
The study cohort consisted of 53 women from the Stockholm (Sweden) center with 
endometrial cancer and complete videoclips of the uterine corpus and cervix, subject to 
preoperative ultrasound examination between June 2011 and October 2012. 
3.1.2 Study II 
The study cohort consisted of 850 women with endometrioid endometrial cancer from eight 
of the nine centers with 50 inclusions or more, subject to preoperative ultrasound examination 
between February 2011 and December 2015. The study cohort originated from five European 
countries (Czech Republic, Italy, Lithuania, Spain and Sweden). 
3.1.3 Study III 
The study cohort consisted of 1501 women with endometrial cancer, excluding one center 
recruiting women (n = 37) from a screening population, subject to preoperative ultrasound 
examination between January 2011 and December 2015. The study cohort originated from 16 
centers in seven European countries (Belgium, Czech Republic, Hungary, Italy, Lithuania, 
Spain, Sweden). 
3.1.4 Study IV 
The study cohort consisted of 339 women from the Stockholm center (Sweden) with 
complete ProMisE analysis, subject to preoperative ultrasound examination between 
February 2011 and December 2015. 
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3.2 METHODS 
3.2.1 Study I 
To enable the assessment of an identical material of multiple cases by multiple users, we 
created a digitalized survey containing videoclips of the uterine corpus and the cervix in 
sagittal section, obtained by the same ultrasound expert prior to surgery. Through the survey, 
nine ultrasound experts, working as second-opinion sonographers around Europe, and nine 
Stockholm based gynecologists, using ultrasound in their everyday work but having no 
experience in ultrasound cancer staging, independently and subjectively evaluated 
myometrial invasion (< 50% / ≥ 50%), cervical stromal invasion (no / yes), videoclip quality 
(visual analogue scale 0—100), and certainty in the assessment (visual analogue scale 0—
100). Each case needed to be finished to proceed to the next, but answers could be changed 
until the survey was submitted. Agreement to histopathology and interobserver 
reproducibility was measured and compared between the ultrasound experts and the 
gynecologists. 
3.2.2 Study II 
Reference pathologists, specialized in gynecological cancer, assessed the presence or the 
absence of the MELF pattern by re-evaluating the pathology slides from the hysterectomy 
specimen. Reference images and written information on the criteria of MELF diagnostics 
were sent to all pathologists, so as to ensure uniformity in assessment between centers. All 
evaluations in one center were done by the same pathologist, so as to ensure a uniform 
assessment within each center. The MELF pattern was confirmed when one of the three 
diagnostic criteria was met; 1) microcystic glands, 2) elongated glands or 3) fragmented small 
solid clusters or single cells. Sonographic features and accuracy of ultrasound assessment of 
myometrial invasion were compared in cases with the presence and the absence of the MELF 
pattern. The association of the MELF pattern to more advanced stage (≥IB) and lymph node 
metastases was assessed using univariable and multivariable logistic regression.  
3.2.3 Study III 
A mixed effects logistic regression model was developed, to calculate the individual risk of 
lymph node metastases. Candidate predictors were selected a priori, to avoid overfitting and 
to create a robust model154. Predictors that were highly subjective or subject to systematic 
measurement errors were not included. The number of predictors was chosen to yield 10 
events per predictor, to guard against estimating too many parameters relative to the sample 
size155. The chosen predictors were age (years), duration of bleeding (months), results of 
preoperative biopsy (histotype and grade), tumor extension according to ultrasound (depth of 
myometrial invasion, cervical stromal invasion, extrauterine spread), endometrial color 
content (color score), tumor size (AP tumor/uterine diameter ratio) and "undefined tumor 
with unmeassurable endometrium", for tumors that could not be defined on ultrasound and 
where the endometrium could not be measured.  
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Missing data was multiply imputed, including lymph node metastases outcomes156 in women 
without lymphadenectomy, assuming missingness not at random and missingness at random. 
Results obtained using imputed outcomes were compared through sensitivity analysis to 
results obtained from complete case analysis. The multivariable fractional polynomial 
algorithm was used to check for nonlinear effects of continuous predictors and 
simultaneously check if any of the a priori chosen predictors were redundant in the 
multivariable model157. The multicenter nature of the data was accounted for by forcing a 
center effect into the multivariable fractional polynomial algorithm. To avoid statistical 
overfitting, regression coefficients were shrunk using a heuristic shrinkage factor158. 
Exclusion of predictors was based on α = 0.2.  
The performance of the model was evaluated using leave-center-out cross validation159. 
Model performance was assessed by the discriminative ability to distinguish women with or 
without lymph node metastases (the area under the receiver operating characteristic (ROC) 
curve and sensitivity and specificity at various risk thresholds), by calibration to evaluate the 
reliability of the calculated risks (intercept, slope and calibration plot) and by clinical utility 
for decision making (decision curve analysis). All measures of model performance in each 
center were combined into global performance estimates using random-effects meta-
analysis160, 161. The predictive performance of the model was compared with risk 
classification from endometrial biopsy alone (high risk: endometrioid cancer grade 3 or non-
endometrioid cancer) and with combined endometrial biopsy and ultrasound (high risk: 
endometrioid cancer grade 3, non-endometrioid cancer, deep myometrial invasion, cervical 
stromal invasion or extrauterine spread). 
3.2.4 Study IV 
The ProMisE subtypes were analyzed retrospectively on formalin-fixed paraffin-embedded 
tumor tissue from a biobank, using immunohistochemistry (MMR-D, p53 wt and p53 abn) 
and gene mutation analysis by DNA sequencing (POLE EDM). Two pathologists reviewed 
all immunohistochemistry stains independently and resolved any interpretative discrepancies 
at a multiheaded microscope. ProMisE classification of the tumors was performed using the 
pragmatic model by Talhouk et al132 (Figure 13). For practical reasons, ProMisE was 
analyzed on tumor tissue from the hysterectomy specimen, but was used as a proxy for the 
preoperative biopsy specimen throughout the study, as agreement between ProMisE on 
diagnostic biopsy and hysterectomy is high133, 135, 136.  
Data on adjuvant treatment, tumor recurrence, tumor progression and survival was obtained 
through review of digital patient files. All women were followed until death, loss of follow-
up or end of follow-up (31 August 2019). Disease-free survival time was defined as time 
from surgery to detection of recurrence or end of follow-up and overall survival time as time 
from surgery until death of any cause or end of follow-up. The women were classified 
according to the pre- and postoperative ESMO classification27 (Table 7).  
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Figure 13. Steps in molecular classification with Proactive Molecular Risk Classifier for Endometrial 
Cancer (ProMisE). Reprinted with permission132 
MMR-D: mismatch repair proteins deficiency; POLE EDM: polymerase-ε exonuclease domain 
mutations; p53wt: protein 53 wild type; p53 abn: protein 53 abnormal. 
 
Cases with cervical stromal invasion and/or extrauterine spread according to ultrasound were 
added to the preoperative ESMO high-risk group. Due to the low number of women, the 
postoperative advanced and metastatic ESMO risk groups were combined.  
Tumors with different ProMisE subtypes (MMR-D, POLE EDM, p53wt and p53 abn) were 
compared with regard to demographic-, sonographic- and histopathologic characteristics and 
to survival data, with special focus on the p53 abn subtype, as it is known to be associated 
with adverse outcome120, 130-132, 136. Variables associated with recurrence or progression were 
identified through univariable and multivariable Cox regression analysis. 
To study if variables associated with progression or recurrence according to multivariable 
Cox regression analysis also had predictive value, they were analyzed using logistic 
regression models with a fixed time (outcome within three years). The predictive ability of 
the logistic regression models (ProMisE model and histotype and grade model) was 
compared to the logistic regression models for pre- and postoperative ESMO classification 
(ESMO pre and ESMO post), using area under the receiver operating characteristic (ROC) 
curves (AUC). 
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Table 7. Risk stratification according to the 2016 ESMO-ESGO-ESTRO Consensus statement 
Conference on Endometrial Cancer27 
Type Risk group Description* 
Preoperative† Low Endometrioid grade 1—2 with MI < 50% 
  Intermediate Endometrioid grade 1—2 with MI ≥ 50% 
    Endometrioid grade 3 with MI < 50% 
  High Endometrioid grade 3 with MI ≥ 50%  
    Non-endometrioid 
      
Postoperative‡  Low Stage I endometrioid, grade 1—2, < 50% MI, LVSI neg 
  Intermediate Stage I endometrioid, grade 1—2, ≥ 50% MI, LVSI neg 
  High intermediate Stage I endometrioid, grade 3, < 50% MI, LVSI neg or pos 
    Stage I, endometrioid grade 1—2, LVSI pos, MI < or  ≥ 50% 
  High Stage I endometrioid, grade 3, ≥ 50% MI, LVSI neg or pos 
    Stage II 
    Stage III without residual disease 
    Non-endometrioid 
  Advanced Stage III with residual disease 
    Stage IVA 
  Metastatic Stage IVB 
*FIGO 2009 staging is used 
†To guide decision on lymphadenectomy 
‡To guide adjuvant therapy use 
LVSI: lymphovascular space invasion; MI: myometrial invasion 
 
3.3 STATISTICAL ANALYSIS 
The chi-square test (Study I) and Fisher's exact test (Study IV) were used for categorical 
data. The t-test was used for normally distributed continuous data (Study I), the Mann-
Whitney U test for non-normally distributed continuous data comparing two groups (Study I, 
II and IV) and the Kruskal-Wallis test for continuous data comparing more than two groups 
(Study IV). McNemars test was used for paired categorical data (Study I). Kappa statistics 
was used for agreement, with Cohen's kappa for a single observer and Fleiss Kappa for 
multiple observers (Study I). Spearman's correlation coefficient was used to assess statistical 
dependence between two variables (Study I). Logistic regression analysis (Study II—IV) 
and Cox regression analysis (Study IV) were used to study crude (univariable analysis) and 
adjusted (multivariable analysis) associations between variables and outcomes. Multiple 
imputation was used to impute missing data (Study III). The multivariable fractional 
polynomial algorithm was used to develop a mixed effects logistic regression model (Study 
III). Leave-center-out cross validation was used to evaluate model performance (Study III). 
Discriminative ability of logistic regression models was assessed through AUC (Study III 
and IV) and sensitivity and specificity at various risk thresholds (Study III). Pairwise 
comparison of AUC was performed using DeLong test (Study IV). Diagnostic performance 
was assessed through sensitivity, specificity (Study I and II), positive predictive value 
(PPV), negative predictive value (NPV) and accuracy (Study II). Decision curve analysis 
was used to assess clinical utility (Study III). Survival analysis (disease-free survival and 
overall survival) was estimated from Kaplan-Meier plots, with the log rank test for testing 
differences in survival (Study IV). P-value < 0.05 was considered statistically significant 
(Study I—IV).  
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An introduction to used statistical methods is given below, in order of appearance in the 
thesis. 
3.3.1 Diagnostic accuracy  
Sensitivity is the ability of a test to correctly identify those with the condition (true positive 
rate) whereas specificity is the ability of a test to correctly identify those without the 
condition (true negative rate). False positive rate (FPR) = 1 - specificity and false negative 
rate (FNR) = 1 - sensitivity. A perfect test would have 100 % sensitivity, i.e. identifying all 
with the condition, and 100 % specificity, i.e. not identifying anyone without the condition as 
having it. Sensitivity and specificity are independent of the percentage of positive cases in the 
population of interest (i.e. the prevalence), in comparison to the predictive values. Positive 
predictive value (PPV) refers to the test making a positive prediction and the subject having a 
positive result and the negative predictive value (NPV) refers to the test making a negative 
prediction and the subject having a negative result. Accuracy corresponds to the proportion of 
correctly classified cases162 (Figure 14). 
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Figure 14. Two-by-two contingency table for diagnostic tests   
NPV; negative predictive value; PPV: positive predictive value 
3.3.2 Interobserver reproducibility 
The kappa (κ) statistics provides a quantitative measure of the magnitude of agreement 
between observers in the interpretation of a specific test and can be measured when two or 
more independent observers evaluate the same material. When measuring interobserver 
reproducibility, one must take into account that observers might agree or disagree simply by 
chance.  
The kappa statistic is based on the difference between "observed agreement" (how much 
agreement is actually present) and “expected agreement” (how much agreement that would 
be expected to be present by chance alone). The result is given on a scale of -1 to +1, where 1 
is perfect agreement, 0 is agreement equivalent to chance and < 0 is agreement less than 
chance (systematic disagreement between observers)163, 164.  
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Kappa values were categorized as "poor" (≤ 0.20), "fair" (0.21—0.40), "moderate" (0.41—
0.60), "good" (0.61—0.80) and "very good) (0.81—1.00)165.  
3.3.3 Logistic regression 
Logistic regression is used to predict a binary outcome (1/0, yes/no, true/false) given one or 
more independent variables. It predicts the probability of an event by fitting data to a logit 
function (log odds). The result is the impact of each variable on the odds ratio (OR) of the 
outcome.  
Odds are the ratio between probabilities, i.e. between the probability of an event favorable to 
an outcome and the probability of an event against the same outcome. The odds ratio is the 
ratio between odds.  
A large odds ratio means that the risk of a particular group is much greater than that of the 
reference group, and may or may not be indicative of a large probability of an outcome. If the 
risk of the reference group is small, even a large odds ratio can indicate a small probability166. 
3.3.4 Multiple imputation 
As there is usually a reason for missing values, exclusion of cases with missing data with 
analysis only on complete cases can lead to a biased sample and poor generalizability. 
Furthermore, it reduces the sample size, with subsequent loss of precision and power. The 
risk of missing data causing bias depends on the reasons why data are missing. Commonly, 
reasons for missing data are classified as; missing completely at random, MCAR (no 
systematic differences between missing and observed values), missing at random, MAR (any 
systematic differences between missing and observed values can be explained by differences 
in observed data) and missing not at random, MNAR (remaining systematic differences 
between the missing and the observed values, even after the observed data are taking into 
account).  
Multiple imputation analysis is a statistical method to deal with missing data. It avoids bias 
induced by systematic differences by allowing also individuals with incomplete data to be 
included in analyses and enables all patient data to be used in the building of a risk prediction 
model. Multiple imputation is especially useful when auxiliary variables, such as 
hysterectomy findings, are available to impute the outcome156.  
In multiple imputation, multiple datasets are created, with replacement of the missing values 
based on their predictive distribution in the observed data. The risk prediction model is fitted 
to each of the imputed datasets and estimated associations are averaged together to give 
overall estimated associations. Bias is avoided only if enough variables predictive of the 
missing values are included in the imputation model167, 168. 
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3.3.5 Leave-center-out cross validation 
If a model is tested on the same multicenter dataset on which it was developed, a cross-
validation procedure can be used that mimics external validation. The model is repeatedly 
developed in all centers but one and validated in the remaining center. If the models perform 
well in leave-center-out cross validation, a model derived from the entire multicenter dataset 
is likely to be generalizable159. 
3.3.6 Receiver Operating Characteristic (ROC) curves 
A ROC-curve is a graphical plot that illustrates the performance of a binary classifier system 
at various discrimination thresholds between 0 and 1. It is created by plotting the true positive 
rate (sensitivity) against the false positive rate (1-specificity) and illustrates how a test or a 
predictive model can discriminate between true positives and true negatives. The diagonal 
reference line represents the ROC curve for a test or model without discriminative ability. 
The further in the upper left the curve of the test or model is from the diagonal line, the better 
the discrimination. The area under the ROC curve (AUC) is the most commonly used ROC 
index. An AUC of 1 reflects a test or model with perfect discrimination whereas an AUC of 
0.5 reflects absent discriminative ability169. 
3.3.7 Calibration analysis 
The calibration plot is a graphical plot of the agreement between predicted and observed 
outcomes. A model that is well calibrated will yield a curve lying on the diagonal, suggesting 
that predicted risks are correct, i.e. among subjects with a predicted risk of 15%, 15 out of 10 
will have the event.  
Ideally, the calibration slope is one and the calibration intercept is zero. A calibration slope 
deviating from one indicates over- or underfitting. Overfitting (slope < 1) yields predicted 
risks in high-risk women that are too high, and predicted risks in low-risk women that are too 
low, while underfitting (slope > 1) yields predicted risks that are too moderate, i.e. high risks 
are underestimated while low risks are overestimated.  
A calibration intercept deviating from zero indicates miscalibration-in-the-large: on average 
in this population, the risk is overestimated (< 0) or underestimated (> 0). Miscalibration-in-
the large can occur simultaneously with over- or underfitting170. 
3.3.8 Decision curve analysis 
Decision curve analysis is a tool to quantify the clinical utility for decision making for a risk 
prediction model. It balances the benefits of true positives against the harms of false positives 
on a single scale, by using a weighting factor for false positives. The weighted factor 
corresponds to the odds of the chosen risk threshold for performing a certain procedure, such 
as biopsy or surgery.  
A risk threshold of 10% corresponds to the odds 1:9, i.e. the benefit of performing the 
procedure in someone with the outcome is considered nine times as large as the harm of 
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performing the procedure in someone without the outcome. The decision curves (net benefit 
vs. risk thresholds) are plotted for the risk prediction model and compared to the default 
strategies of performing the procedure in all and in none. If one curve is highest over the full 
range of probability thresholds, then that diagnostic approach is the best171, 172. 
3.3.9 Cox regression 
Cox regression analysis, also called proportional hazards regression, investigates the 
relationship of predictors and the time-to-event through a hazard function. It differs from 
logistic regression by assessing a rate (the number of new cases of an outcome per population 
at risk per unit of time, i.e. the incidence or hazard rate) instead of a proportion (the 
proportion of new cases that develop in a given time period, i.e. the cumulative incidence).  
Unlike logistic regression, Cox regression is dependent on time. The Cox regression analysis 
estimates the hazard ratio (HR), which can be interpreted as the relative risk of the event 
occurring at time t, or the relative event rate. A HR > 1 means that the event is more likely to 
occur, and a HR < 1 that the event is less likely to occur. If the HR = 1, the predictor has no 
effect on the hazard of the event173.  
3.3.10 Kaplan-Meier analysis 
The Kaplan-Meier curve is a graphical method for displaying survival or time-to-event 
analysis. The Kaplan-Meier curve shows what the probability of an event is at a certain time 
interval. The horizontal axis represents the time from enrollment, corresponding to the time at 
which participants are considered at-risk for the outcome of interest, and the vertical axis 
represents the estimated probability of survival, i.e. cumulative survival. Each downward step 
in the lines represents an event (the outcome of interest), while each small vertical tick 
represents a censored observation. Censoring means that the total survival time for that 
subject cannot be accurately determined. This occurs when the individual drops out of the 
study, is lost to follow-up or the study ends before the subject had the event of interest. With 
time, fewer people remain at risk. Survival curves can be compared using the HR or through 
the log rank test174.  
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4 RESULTS 
4.1 STUDY I 
No significant difference could be found between ultrasound experts and gynecologists in the 
diagnostic accuracy and agreement with histopathology for deep myometrial invasion. 
However, ultrasound experts had significantly higher diagnostic accuracy and greater 
agreement to histopathology for cervical stromal invasion (Table 8). Ultrasound experts rated 
their certainty as being greater than did gynecologists, in the assessment of both deep 
myometrial invasion and cervical stromal invasion (Table 8). Certainty in assessment, for 
ultrasound experts and gynecologists combined, was correlated with correct assessment of 
both deep myometrial invasion and cervical stromal invasion (correlation coefficient 0.49, p 
< 0.01 vs. 0.62, p < 0.01, respectively). Ultrasound experts and gynecologists assessed 
videoclip quality similarly, regarding both deep myometrial invasion and cervical stromal 
invasion (Table 8). Videoclip quality, for ultrasound experts and gynecologists combined, did 
not affect the correct assessment of deep myometrial invasion, but was correlated to correct 
assessment of cervical stromal invasion (correlation coefficient 0.24, p = 0.08 vs. 0.36, p = 
0.01). Neither BMI nor preoperative risk (low risk: endometrioid cancer grade 1—2 and high 
risk: endometrioid cancer grade 3 or non-endometrioid cancer) did affect correct assessment 
of deep myometrial invasion or cervical stromal invasion (BMI: correlation coefficient 0.04, 
p = 0.8 vs. -0.11, p = 0.4, respectively; preoperative risk: correlation coefficient 0.74 vs. 0.63, 
p = 0.4 and 0.80 vs. 0.76, p = 0.6, respectively).  
 
Table 8. Assessment of deep myometrial invasion (≥ 50%) and cervical stromal invasion by 
ultrasound experts and gynecologists 
a. Deep myometrial invasion 
  Ultrasound experts Gynecologists   
  Value 95% CI Value 95% CI p* 
Sensitivity (%) 73 66 —79 73 66 —79 1.00 
Specificity (%) 69 63 —74 70 65—75 0.68 
Kappa† 0.52 0.48 —0.57 0.48 0.44 —0.53 0.11 
Certainty (VAS) 74 63 —84 56 48 —65 < 0.01 
Quality (VAS) 64 52 —77 56 50 —63 0.23 
            
b. Cervical stromal invasion 
 
    
  Ultrasound experts Gynecologists   
  Value 95% CI Value 95% CI p* 
Sensitivity (%) 57 45 —68 42 31 —53 <0.01 
Specificity (%) 87 83 —90 83 78 —86 0.02 
Kappa† 0.58 0.53 —0.62 0.45 0.40 —0.49 <0.01 
Certainty (VAS) 77 65 —89 58 48 —68 0.01 
Quality (VAS) 71 57 —85 59 53 —64 0.07 
Certainty: certainty in assessment, as measured on a visual analogue scale 
Quality: experienced videoclip quality, as measured on a visual analogue scale 
* Mc Nemar's test † Fleiss kappa for multiple observers 
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Interobserver reproducibility for deep myometrial invasion did not differ between ultrasound 
experts and gynecologists. The test proportion "good" and "very good" was 34% vs. 22% (p 
= 0.13), respectively. Interobserver reproducibility for cervical stromal invasion was 
significantly higher for ultrasound experts compared to gynecologists, with a test proportion 
"good" and "very good" of 53% vs. 14% (p < 0.01) (Table 9). 
Table 9. Interobserver reproducibility of ultrasound experts and gynecologists in the assessment of 
deep myometrial invasion (≥ 50 %) and cervical stromal invasion 
  Deep myometrial invasion n (%)   Cervical stromal invasion n (%) 
Kappa Ultrasound experts Gynecologists   Ultrasound experts Gynecologists 
Poor (< 0.20) 0 (0) 0 (0) 
 
0 (0) 3 (8) 
Fair (0.21—0.40) 7 (19) 7 (19) 
 
4 (11) 11 (31) 
Moderate (0.41—0.60) 27 (47) 21 (58) 
 
13 (36) 17 (47) 
Good (0.61—0.80) 11 (31) 8 (22) 
 
19 (53) 5 (14) 
Very good (0.81—1.00) 1 (3) 0 (0)   0 (0) 0 (0) 
 
4.2 STUDY II 
The MELF pattern was found in 23% of the women, and was associated with older age (68 
vs. 64 years, p < 0.01), lower body mass index (BMI) (29 vs. 30, p < 0.01), post-menopausal 
status (95% vs. 87%, p < 0.01), deep myometrial invasion (52% vs. 28%, p < 0.01), cervical 
stromal invasion (13% vs. 8%, p =0.04), lymph node metastases (26% vs. 14%, p = 0.01) and 
higher stage (stage ≥IB: 56% vs. 33%, p < 0.01) but not with high-grade (grade 3: 16% vs. 
18%, p =0.51).  
Tumors with the MELF pattern were two to three times more likely to have deep myometrial 
invasion (OR 2.8, 95% CI 2.0—3.9, p < 0.01), cervical stromal invasion (OR 1.7, 95% CI 
1.0—2.9, p = 0.04), higher stage (stage ≥IB: OR 2.6, 95% CI 1.9—3.6, p < 0.01) and lymph 
node metastases (OR 2.2, 95% CI 1.2—4.0, p = 0.01) in univariable analysis.  
On preoperative ultrasound, tumors with the MELF pattern were slightly larger (endometrial 
thickness 20 mm vs. 18 mm, p = 0.03), had a higher endometrial color score (score 3—4: 
68% vs. 56%, p < 0.01) and more often the multiple multifocal vascular pattern (48% vs. 
34%, p < 0.01), whereas little difference was seen in the assessment of endometrial 
morphology (non-uniform echogenicity: 68% vs. 62%, p = 0.11; non-regular endometrial-
myometrial junction: 82% vs. 75%, p = 0.06; bright edge present: 9% vs. 13%, p = 0.11).  
Ultrasound assessment of deep myometrial invasion was not affected by the MELF status, as 
there was no difference in sensitivity of specificity compared to tumors with and without the 
MELF pattern. The positive predictive value was higher and the negative predictive value 
lower in tumors with the MELF pattern (Table 10). Ultrasound underestimated myometrial 
invasion to the same degree in tumors with and without the MELF pattern (29.1% vs. 29.5%, 
p = 0.95). 
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Table 10. Sonographic assessment of deep myometrial invasion in relation to the MELF pattern (%) 
  No MELF MELF p* 
Sensitivity 71 71 0.95 
Specificity 79 76 0.41 
Accuracy 77 73 0.28 
PPV 57 76 < 0.01 
NPV 87 70 < 0.01 
* χ2 test 
PPV: positive predictive value; NPV negative predictive value 
 
According to histopathology, MELF status and grade were significantly associated to higher 
stage (≥IB) in both univariable- and multivariable analysis. MELF, deep myometrial invasion 
and cervical stromal invasion, but not grade, were significantly associated with lymph node 
metastases in univariable analysis, whereas only deep myometrial invasion and cervical 
stromal invasion remained significantly associated to lymph node metastases in multivariable 
analysis (Table 11).  
 
Table 11. Univariable- and multivariable logistic regression analysis modeling stage ≥ IB (n = 850) 
and lymph node metastases (n = 348)  
a. Stage ≥ IB 
  Univariable analysis Multivariable analysis* 
  OR 95 % CI p OR 95 % CI p 
MELF present 2.6 1.9—3.6 < 0.01 2.3 1.6—3.2 < 0.01 
Grade 1 Ref     Ref     
Grade 2 2.6 1.9—3.7 < 0.01 2.4 1.7—3.4 < 0.01 
Grade 3 4.7 3.1—7.2 < 0.01 4.6 3.0—7.2 < 0.01 
MI ≥ 50% —     —     
CSI —     —     
MI < 50%, no CSI —     —     
MI ≥ 50%, no CSI —     —     
CSI, MI <50% /  ≥ 50% —     —     
       b. Lymph node metastases 
      Univariable analysis Multivariable analysis* 
  OR 95 % CI p OR 95 % CI p 
MELF present 2.2 1.2—4.0 0.01 1.8 0.9—3.5 0.09 
Grade 1 Ref      Ref     
Grade 2 1.4 0.6—3.3 0.51 1.0 0.4—2.7 0.94 
Grade 3 2.4 1.0—5.9 0.06 2.1 0.7—5.7 0.16 
MI ≥ 50% 8.0 3.8—16.8 < 0.01 —     
CSI 4.0 2.1—7.6 < 0.01 —     
MI < 50%, no CSI Ref     Ref     
MI ≥ 50%, no CSI 5.6 2.5—12.2 < 0.01 4.9 2.2—11.4 < 0.01 
CSI, MI <50% /  ≥ 50% 10.8 4.5—25.8 < 0.01 9.6 3.9—23.8 < 0.01 
*Adjusted for age, body mass index and menopausal status 
CI: confidence interval; CSI: cervical stromal invasion; MELF: microcystic, elongated and 
fragmented; MI: myometrial invasion 
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4.3 STUDY III 
Median age was 65 years and the majority of the women (87%) reported abnormal bleeding, 
with a median bleeding duration of three months. Most women had low-grade endometrioid 
cancer in the preoperative biopsy (69%) and tentative stage IA, according to preoperative 
ultrasound (60%). Of the 691 women (46%) subject to lymphadenectomy, lymph node 
metastases were present in 127 (18%). Of the 252 women (17%) with undefined tumor on 
ultrasound, the AP tumor diameter was replaced by endometrial thickness when measurable 
(15%), or was accounted for as a separate variable when not measurable (2%). Preoperative 
grade was missing in 75 women (5%) and lymph node status in 810 women (54%), and were 
multiply imputed.  
The preoperative predictors are presented in Table 12. The color Doppler score did not meet 
the criterion for inclusion (α = 0.2) and was not retained as a predictor. High-grade did not 
add to the risk of lymph node metastases, when adjusting for the other predictors. 
Table 12. Adjusted associations between the preoperative predictors and the presence of lymph node 
metastases on the basis of logistic regression (n = 1501) 
Predictor	 OR	 95	%	CI	
Intercept	 	 	
Age	(per	10	years)	 1.16	 0.92—1.48	
Bleeding	duration	(per	3	months)	 1.09	 0.99—1.20	
Endometrial	biopsy	 	 	
		 Endometrioid	grade	1—2	 Ref	 	
		 Endometrioid	grade	3	 0.92	 0.52—1.65	
		 Non-endometrioid	 2.01	 1.22—3.33	
		 Other*	 1.89	 0.58—6.12	
Ultrasound	tumor	extension	 	 	
		 MI	<	50%,	no	CSI	 Ref	 	
		 MI	≥50%,	no	CSI	 1.75	 1.00—3.07	
		 CSI	±	MI	≥	50%	 1.77	 0.84—3.70	
		 Extrauterine	spread	 5.86	 2.98—11.88	
Color	Doppler†	 	 	
		 Score	1—2	 Ref	 	
		 Score	3—4	 1.20	 0.68—2.10	
		 Invisible	endometrium	 1.01	 0.36—2.87	
AP	tumor/uterine	diameter	ratio	(per	0.25)	 1.49	 1.13—1.97	
Undefined	tumor	with	unmeasurable	
endometrium	
3.41	 0.76—15.22	
Exclusion of predictors was based on α = 0.2, hence 95 % CI including 1 is not sufficient for 
exclusion 
* Biopsy with complex atypical hyperplasia or no biopsy, but ultrasound findings consistent with 
cancer 
† Not retained (p > 0.2) 
AP: anteroposterior; CI: confidence interval; CSI; cervical stromal invasion; MI: myometrial 
invasion 
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The model formula is presented in Figure 15. The individual risk of lymph node metastases is 
obtained by multiplying each predictor by its regression coefficient and the addition of the intercept.		The	overall AUC of the risk prediction model is 0.73 (95 CI 0.68—0.78). The model is well 
calibrated (calibration slope 1.06 and calibration intercept 0.06), meaning that predicted risks 
correspond well to observed lymph node metastases frequencies. The adjusted odds ratios 
(Table 12) indicate that the model predicts the risk of lymph node metastases better than the 
use of biopsy only or combined biopsy and ultrasound, as additional model inputs contribute 
to the prediction of lymph node metastases even if ultrasound tumor extension and biopsy 
results are taken into account. For example, a 3-month increase in bleeding duration increases 
the odds of lymph node metastases with 9% (adjusted OR 1.09, 95% CI 0.99—1.20).  
 
Probability (lymph node metastases = yes) = !!!!"#(!!") 
 
Xβ = 
-3.962 
+ 0.134 × (age in years / 10) 
+ 0.072 × (duration of abnormal bleeding in months / 3) 
+ 0.607 × (1 if non-endometrioid cancer on endometrial biopsy, 0 otherwise) 
+ 0.592 × (1 if clinical suspicion of cancer*, 0 otherwise) 
+ 0.502 × (1 if MI ≥ 50% without CSI or extrauterine spread on ultrasound, 0 otherwise) 
+ 0.512 × (1 if CSI without extrauterine spread on ultrasound, 0 otherwise) 
+ 1.533 × (1 if extrauterine spread on ultrasound, 0 otherwise} 
+ 0.359 × (AP tumor/uterine diameter ratio / 0.25) 
+1.046 × (1 if undefined tumor with unmeasurable endometrium, 0 otherwise) 
	
Figure 15. Model formula with regression coefficients obtained by heuristic shrinkage 
*Endometrial biopsy with other diagnosis, e.g. complex atypical hyperplasia, or no biopsy, but 
ultrasound findings consistent with cancer 
AP: anteroposterior; CSI: cervical stromal invasion; MI: myometrial invasion 
Whereas risk stratification by biopsy only or combined biopsy and ultrasound have fixed 
sensitivity and specificity levels, the model threshold can be shifted upward, for a better 
specificity, or downward for a better sensitivity (Table 13). The lower the risk threshold, the 
more lymph node metastases are correctly identified, but at the cost of a higher number of 
unnecessary lymphadenectomies. When setting the model threshold to give equally large test 
positive groups as biopsy only and combined biopsy and ultrasound, the risk prediction 
model proved superior, as it was associated with higher sensitivity without any loss of 
specificity (Table 13).  
 
 
 38 
Table 13. Model performance depending on risk threshold in distinguishing between women with and 
without lymph node metastases and comparison between the risk prediction model and risk-
classification by preoperative biopsy alone or combined biopsy and ultrasound (n = 1501) 
Model	risk	threshold	 Test	positive	 95	%	CI	 Sensitivity	 95	%	CI	 Specificity	 95	%	CI	
0.03	 97	 96—98	 99	 94—100	 3	 2—4	
0.05	 90	 88—92	 98	 92—99	 11	 9—14	
0.1	 58	 54—62	 83	 76—89	 47	 41—52	
0.15	 39	 35—43	 67	 58—75	 66	 61—71	
0.2	 24	 21—28	 48	 39—56	 80	 75—85	
0.3	 9	 7—12	 25	 18—33	 94	 90—96	
0.4	 4	 3—6	 13	 8—20	 97	 95—99	
0.5	 2	 1—3	 5	 3—11	 99	 97—100	
		 		 		 		 		 		 		
Comparison	of	the	model,	biopsy	alone	and	combined	biopsy	and	ultrasound	
0.196*	 25	 22—29	 50	 41—58	 80	 74—84	
Biopsy†	 25	 21—29	 35	 27—44	 77	 72—82	
0.113*	 52	 48—56	 80	 71—86	 53	 47—58	
Biopsy	+	ultrasound‡	 52	 47—57	 75	 66—81	 52	 46—59	
Results are from leave-center-out cross validation 
*Model thresholds chosen to give equally large test positive groups as "Biopsy" and "Biopsy and 
ultrasound" 
† Endometrial biopsy (endometrioid grade 3/non-endometrioid) 
‡ Endometrial biopsy (endometrioid grade 3/non-endometrioid) and ultrasound extension (deep 
myometrial invasion/cervical stromal invasion/extrauterine spread) 
The clinical utility of the competing strategies were compared using decision curve analysis, 
together with the default strategies of conducting lymphadenectomy in all and in none (Figure 
16). The model proved superior to biopsy only and combined biopsy and ultrasound, as the 
net benefit curve of the model was higher over all risk thresholds, indicating better outcomes 
when the harms of false positives (unnecessary lymphadenectomies) and false negatives 
(missed lymph node metastases) are taken into account.  
 
Figure 16. Decision curves representing the net benefit of the risk model, combined biopsy and 
ultrasound, biopsy alone, lymphadenectomy in everyone and lymphadenectomy in none for risk 
thresholds between 3% and 50%. Results are from leave-center-out cross validation.  
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4.4 STUDY IV 
Median follow-up time from surgery was 58 months. Recurrence or progression occurred in 
15% of all women (14% of MMR-D, 8% of POLE, 9% of p53 wt and 46% of p53 abn). 
Compared to those without, the 51 women with recurrence or progression were older (70 vs. 
66 years, p <0.01), had larger waist-circumference (105 cm vs. 93 cm, p  = 0.02), more 
advanced tumor extension on ultrasound (deep myometrial invasion, cervical stromal 
invasion or extrauterine spread: 69% vs. 29%, p < 0.01), larger ultrasound tumor size (AP 
diameter ≥ 2 cm: 83% vs. 36%, p < 0.01), higher endometrial color score (score 3—4: 78% 
vs. 62%, p =0.04), higher tumor stage (stage ≥ IB: 80% vs. 32%, p = < 0.01), more non-
endometrioid cancer (39% vs. 10%, p < 0.01) and the ProMisE p53 abn subtype (39% vs. 
8%, p < 0.01). The vast majority of recurrences (88%) occurred within three years, and all 
tumor progressions occurred within two years.  
Compared to the other ProMisE subtypes, women with p53 abn had a significantly higher 
probability of recurrence or progression (46% vs. 11%, p < 0.01) (Figure 17), were older (70 
years vs. 67 years, p = 0.04), had larger ultrasound tumor size (AP diameter 26 mm vs. 17 
mm, p < 0.01), more often non-endometrioid cancer (77% vs. 5%, p < 0.01), higher stage 
(stage ≥II: 41% vs. 15%, p <0.01), decreased 5-year disease free survival (51% vs. 86%, p < 
0.01) and more often death from disease (39% vs. 5%, p < 0.01).  
 
 
Figure 17. Kaplan-Meier plot on recurrence or progression for the Proactive Molecular Risk 
Classifier for Endometrial Cancer (ProMisE) subtypes (n = 339) 
Overall p < 0.01  
MMR-D vs. p53 abn: p < 0.01 
POLE EDM vs. p53 abn: p < 0.01 
p53 wt vs. p53 abn: p < 0.01 
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Multivariable Cox regression analysis, with all significant preoperative variables from 
univariable analysis, revealed that age ≥ 65 years, waist circumference ≥ 88 cm, ProMisE, 
ultrasound tumor extension and ultrasound tumor AP diameter ≥ 2 cm were independently 
associated with recurrence or progression (Table 14), an association that remained also when 
we adjusted for the postoperative ESMO classification. When ProMisE was removed from 
the multivariable analysis, histotype and grade also became significantly associated with the 
outcome, indicating an interaction between these two variables. Hence, ProMisE and 
histotype and grade were accounted for in separate models.  
Table 14. Multivariable Cox regression analysis; associations of preoperative variables on tumor 
recurrence or progression (n=339) 
		 		 		
All	variables	significant	in	
univariable	analysis	
Histotype	and	grade	model	 ProMisE	model	
		 		 		 HR	 95	%	CI	 p*	 HR	 95	%	CI	 p*	 HR	 95	%	CI	 p*	
Demographic	variables	 		 		 		 		 		 		 		 		 		
		 Age	(years)		 		 		 <	0.01	 		 		 <	0.01	 		 		 <	0.01	
		 		 <	65	 Ref	 		 		 Ref	 		 		 Ref	 		 		
		 		 ≥	65	 4.0	 1.7—9.5	 		 4.4	 2.0—9.8	 		 3.8	 1.7—8.4	 		
		 Waist	circumference	(cm)		 		 		 0.01	 		 		 0.01	 		 		 0.02	
		 		 <	88	 Ref	 		 		 Ref	 		 		 Ref	 		 		
		 		 	≥	88	 2.6	 1.2—5.6	 		 2.5	 1.2—5.1	 		 2.5	 1.2—5.1	 		
Histopathological	variables	 		 		 		 		 		 		 		 		 		
		 Histotype	and	grade	 		 		 0.40	 		 		 <	0.01	 		 		 		
		 		 Endometrioid	grade	1—2	 Ref	 		 		 Ref	 		 		 —	 —	 		
		 		 Endometrioid	grade	3	 2.0	 0.8—5.0	 		 2.6	 1.1—6.0	 		 —	 —	 		
		 		 Non-endometrioid	 1.9	 0.7—4.8	 		 4.4	 2.3—8.2	 		 —	 —	 		
		 		 Other†	 0.8	 0.2—3.5	 		 0.8	 0.2—3.4	 		 —	 —	 		
		 ProMisE	 		 		 0.04	 		 		 		 		 		 <	0.01	
		 		 p53	wt	 Ref	 		 		 —	 —	 		 Ref	 		 		
		 		 MMR-D	 1.1	 0.5—2.4	 		 —	 —	 		 1.1	 0.5—2.4	 		
		 		 POLE	EDM	 1.0	 0.2—5.1	 		 —	 —	 		 1.3	 0.3—6.3	 		
		 		 p53	abn		 3.9	 1.3—11.1	 		 —	 —	 		 5.7	 2.8—11.7	 		
Ultrasound	variables	 		 		 		 		 		 		 		 		 		
		 Tumor	extension	 		 		 <	0.01	 		 		 <	0.01	 		 		 <	0.01	
		 		 MI	<	50%,	no	CSI	 Ref	 		 		 Ref	 		 		 Ref	 		 		
		 		 MI	≥	50%,	no	CSI	 1.4	 0.5—3.5	 		 1.4	 0.6—3.0	 		 1.6	 0.7—3.5	 		
		 		 CSI	present	±	MI	≥	50	%		 1.8	 0.6—5.5	 		 2.2	 0.9—5.3	 		 2.2	 0.9—5.4	 		
		 		 Extrauterine	spread	 9.7	 3.0—30.7	 		 7.4	 2.8—19.7	 		 11.
5	
4.2—31.0	 		
		 Tumor	AP	diameter	(cm)	 		 		 <	0.01	 		 		 <	0.01	 		 		 0.01	
		 		 <2	 Ref	 		 		 Ref	 		 		 Ref	 		 		
		 		 	≥	2	 4.7	 1.8—12.4	 		 3.9	 1.6—9.7	 		 3.8	 1.6—9.4	 		
		 		 Tumor	not	defined	 5.3	 1.02—27.2	 		 4.2	 1.1—16.7	 		 3.8	 0.96—15.3	 		
		
Endometrial-myometrial	
junction‡	
		 		 0.30	 		 		 		 		 		 		
		 		 Regular	 Ref	 		 		 —	 		 		 —	 —	 		
		 		 Irregular/interrupted/undef
ined	
2.0	 0.6—7.4	 		 —	 		 		 —	 —	 		
		 Endometrial	morphology‡	 		 		 0.30	 		 		 		 		 		 		
		 		 Uniform	 Ref	 		 		 —	 		 		 —	 —	 		
		 		 Non-uniform	 1.3	 0.7—2.4	 		 —	 		 		 —	 —	 		
		 Color	score‡	 		 		 0.07	 		 		 		 		 		 		
		 		 1—2	 Ref	 		 		 —	 		 		 —	 —	 		
		 		 3—4	 0.4	 0.2—1.1	 		 —	 		 		 —	 —	 		
		 Vascular	pattern‡	 		 		 0.60	 		 		 		 		 		 		
		 		 Other	 Ref	 		 		 —	 		 		 —	 —	 		
		 		 Multiple	multifocal	 1.2	 0.5—3.0	 		 —	 		 		 —	 —	 		
* Test of variable including all categories 
† Endometrioid cancer not graded (n=5), suspicion of endometrial cancer (n=24), no biopsy (n=1) 
‡ In the 332 cases with visible endometrium on ultrasound 
AP: anteroposterior; CI: confidence interval; CSI: cervical stromal invasion; MI: myometrial 
invasion; undef: undefined 
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Ultrasound tumor size remained significantly associated to recurrence or progression in all 
versions of multivariable analysis. In women with defined tumor on ultrasound (n = 317), 
tumors with AP diameter ≥ 2 cm, as compared to < 2 cm, were associated with deep 
myometrial invasion (56% vs. 16%, p < 0.01), lymph node metastases (30% vs. 7%, p = 
0.03), worse 5-year overall survival (78% vs. 93%, p < 0.01) and higher risk of recurrence or 
progression, also among the 154 women with preoperative ESMO low risk (15% vs. 3%, p = 
0.03).  
Stratification by tumor size (tumor AP diameter < 2 cm vs. ≥ 2 cm) and p53 abn status (non-
p53 abn vs. p53 abn) identified a large group of women (48% of the study population) with a 
very low risk of recurrence or progression (1.8%) (Figure 18).  
 
 
 
Figure 18. Risk of recurrence or progression in relationship to p53 abn status and ultrasound tumor 
size (n = 317). 
Non-p53 abn: MMR-D, POLE EDM or p53 wt.  
Tumor < 2 cm vs. ≥ 2 cm: anteroposterior tumor diameter < 2 cm vs. ≥ 2 cm 
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The ProMisE model predicted recurrence or progression with comparable ability as the 
histotype and grade model (AUC 0.89 vs. 0.88, p = 0.22) and with higher ability than both 
preoperative ESMO classification (AUC 0.89 vs. 0.74, p < 0.01) and postoperative ESMO 
classification (AUC 0.89 vs. 0.79, p < 0.01) (Figure 19).  
 
 
 
Figure 19. Receiver operating characteristic curves of predictive ability for recurrence or 
progression in endometrial cancer (n = 339). 
ESMO pre (preoperative ESMO classification): AUC 0.74 (95% CI 0.67—0.82) 
ESMO post (postoperative ESMO classification): AUC 0.79 (95% CI 0.72—0.86) 
Histotype and grade model: AUC 0.88 (95% CI 0.83—0.92) 
ProMisE model: AUC 0.89 (95% CI 0.85—0.93) 
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5 DISCUSSION 
In this thesis on ultrasound assessment and risk prediction in women with endometrial cancer, 
we report that preoperative ultrasound staging is best performed by ultrasound experts, as 
they assess cervical stromal invasion with greater accuracy and interobserver reproducibility 
than gynecologists (Study I), that tumors with presence of the MELF pattern are more than 
twice as likely to have more advanced	stage	(	≥	IB)	and	lymph	node metastases but that the 
MELF pattern does not affect the diagnostic accuracy to assess myometrial invasion by 
ultrasound (Study II), that the individual risk of lymph node metastases can be reliably 
estimated by a preoperative risk prediction model with variables from endometrial biopsy 
results, clinical and ultrasound characteristics (Study III) and that demographic, sonographic 
and ProMisE variables have the potential to predict the risk of recurrence or progression 
already before surgery (Study IV). 
5.1 ULTRASOUND IN THE PREDICTION OF DEEP MYOMETRIAL INVASION 
AND CERVICAL STROMAL INVASION 
Why is it important to accurately predict deep myometrial invasion and cervical stromal 
invasion before surgery in women with endometrial cancer? Deep myometrial invasion is 
predictive of lymph node metastases5, 10, 13-16, 18-22, 24, 25, recurrence and survival7, 8 and 
presence of cervical stromal invasion confers a higher stage, associated with worse survival7. 
Because of the increased risk of adverse outcome, preoperative assessment of deep 
myometrial invasion and cervical stromal invasion is included in preoperative risk 
classification27, contributing to the decision on lymphadenectomy. If the preoperative 
assessment is incorrect, it affects the risk classification with subsequent risk of under- or 
overtreatment.  
Deep myometrial invasion and cervical stromal invasion in Study I was assessed 
subjectively, as subjective assessment is associated with better performance than the use of 
measurement techniques54-56. Reported sensitivities and specificities were in the lower range 
of other publications (Table 2), most likely due to the fact that the ultrasound experts could 
not perform live examinations. Had the primary aim been diagnostic accuracy and not 
interobserver reproducibility, another study design would have been warranted.  
We reported greater diagnostic accuracy and interobserver reproducibility in the assessment 
of cervical stromal invasion by ultrasound experts compared to gynecologists (Table 8 and 
Table 9), and the recommendation that ultrasound staging is best performed by ultrasound 
experts has been implemented in international guidelines27. No difference was seen between 
ultrasound experts and gynecologists in the assessment of deep myometrial invasion (Table 8 
and Table 9). Possibly could dedicated training programs for gynecologists raise their 
prediction of cervical stromal invasion to that of ultrasound experts, which could be valuable 
in areas without access to ultrasound experts and aid in the referral of women with high-risk 
cancer to tertiary cancer centers for surgery.  
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Though obesity may limit the possibility to assess the endometrium, by putting the uterus in 
the upright position39, BMI did not affect correct assessment of neither deep myometrial 
invasion nor cervical stromal invasion, which is in agreement with a publication on factors 
associated with staging error, where neither BMI nor uterine position or image quality were 
associated with over- or underestimation63.  
According to Study II, deep myometrial invasion and cervical stromal invasion was 
approximately 2—3 times more likely in tumors with the MELF pattern, compared to tumors 
with conventional myometrial invasion. However, the presence of the MELF pattern did not 
affect the preoperative ultrasound staging, as sensitivity and specificity for deep myometrial 
invasion did not differ in tumors with and without presence of the MELF pattern (Table 10). 
The higher PPV and the lower NPV in tumors with the presence of the MELF pattern is 
consistent with their increased likelihood of deep myometrial invasion. That significance for 
the MELF pattern was not reached in multivariable analysis modeling lymph node metastases 
was likely due to the fact that the study was not primarily designed for this outcome, and was 
probably underpowered for this analysis, as only 348 women in the study underwent 
lymphadenectomy.  
In Study IV, deep myometrial invasion was significantly more common in tumors with AP 
diameter ≥ 2 cm, verifying that the risk of deep myometrial invasion increases with tumor 
size12, 44, 56, 69, 175.  
A recent publication shows that the addition of dynamic contrast-enhanced ultrasound 
improved the detection of deep myometrial invasion and cervical stromal invasion without 
any increase in the false positive rate176 and hence has the possibility to improve preoperative 
risk classification.  
5.2 THE CHALLENGE OF CORRECT PREDICTION OF LYMPH NODE 
METASTASES 
Diagnostic imaging modalities alone have been shown to predict lymph node metastases with 
high specificity but low sensitivity (ultrasound: 100% vs. 33%58, MRI: 95% vs. 59%76, 
PET/CT: 93% vs. 74%52). Several known prognostic factors, such as grade, stage, depth of 
myometrial invasion and tumor size are predictive of the risk of having lymph node 
metastases5-7, and current risk classification systems (Table 4) and preoperative risk 
prediction models (Table 5) combine such prognostic factors, with the aim of improved risk 
assessment.  
Ultrasound is already an established modality in the preoperative risk classification for 
women with endometrial cancer, in combination with information on histotype and grade 
from preoperative biopsy27. In Study III, we assessed how ultrasound, together with 
variables from endometrial biopsy and clinical characteristics can predict the individual risk 
of lymph node metastases before surgery, by developing a risk prediction model on a large 
prospective cohort (n = 1501). Individual risk assessment enables individualized decision 
making, as higher risks may be deemed acceptable in older, sicker women than in younger, 
  45 
relatively healthy women. The model performed better than risk classification using 
ultrasound and biopsy, as recommended in international guidelines27.  
Though grade is an established risk factor for lymph node metastases5-7 and is included in the 
major risk classification systems (Table 4), it had no prognostic significance when adjusting 
for the other model predictors (Table 12). When replacing grade according to biopsy with 
grade according to hysterectomy, grade did prove to be an independent predictor (grade 1—2 
vs. grade 3: OR 1.9, 95% CI 1.2—2.9). This supports the findings of a Meta-analysis107 that 
there is only moderate agreement on tumor grade between preoperative biopsy and the 
hysterectomy specimen. This, together with the limited interobserver reproducibility for 
grade78, 102, 103, limits its use in preoperative risk assessment.  
The model risk threshold is flexible, and can be adjusted depending on the clinical context, as 
opposed to those models with fixed risk groups25, 145, 146, 149. When choosing the risk 
threshold, one must decide what is more important: to find those with lymph node metastases 
(high sensitivity) or to avoid unnecessary lymphadenectomies (high specificity). An ideal risk 
model would give both at the same time.  
Most preoperative risk classification systems and risk prediction models aim at identifying a 
low-risk group, where lymphadenectomy can be safely omitted152. The definition of what 
"low risk" is varies with models. Our model identified only 10% of the study cohort as having 
a low risk of lymph node metastases (defined as < 5%). Ideally, this group would have been 
larger. At the same time, results from leave-center-out cross validation indicate that the model 
is well calibrated, and that the predicted risks correspond well to the observed frequencies of 
lymph node metastases, which indicate that actually not more than 10% of women might 
have a risk lower than 5%. This needs to be established in an external validation cohort. 
Published preoperative risk prediction models for lymph node metastases have all been 
developed on smaller (n = 110—360) retrospective cohorts, differ in FIGO staging system 
(FIGO 1988 vs. FIGO 2009), use a vast variety of variables, use various modes of imaging 
(ultrasound vs. MRI), define "low risk" differently and have different target populations 
(endometrioid cancer vs. endometrioid or non-endometrioid cancer, and tentative stage IA vs. 
I—II vs. I-IV) (Table 5). The only way to compare the predictive performance of our model 
to that of the others would be in an independent external validation study. If external 
evaluation confirms the predictive ability of our model, it could be made more user-friendly 
by integration into ultrasound machines or apps.  
The use of sentinel node biopsy will bring information on lymph node status on most women, 
also those at low risk, previously not eligible for lymphadenectomy. This limits the need for 
multiple imputation of lymph node status in the development of future risk prediction models, 
and could possibly result in models with higher predictive ability.  
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5.3 PREDICTING RECURRENCE BEFORE SURGERY 
Preoperative risk assessment is normally used to estimate the risk of lymph node metastases, 
whereas the risk of adverse outcome is assessed from postoperative risk assessment, on the 
basis of hysterectomy variables and surgical stage, known only after performed surgery. 
Would it be an advantage if we could predict the risk of recurrence already before surgery? 
ProMisE might constitute a more objective variable than histotype and grade, by being based 
on the presence or absence of a protein or a mutation. In comparison to grade107, ProMisE is 
associated with a high concordance between preoperative biopsy and hysterectomy 
specimen133, 135, 136, making it potentially suitable for preoperative risk assessment. 
In Study IV, we explored the possibility to use ultrasound, clinical characteristics and 
ProMisE to predict tumor recurrence or progression in the preoperative setting. We found that 
a model including demographic (age ≥ 65 years, waist circumference ≥ 88 cm), sonographic 
(tumor extension and ultrasound tumor AP diameter ≥ 2 cm) and ProMisE variables predicted 
the risk of recurrence or progression with comparable ability as the corresponding model with 
histotype and grade, and with higher ability than the ESMO classification (Figure 19), and 
that non-p53 abn status and ultrasound tumor AP diameter < 2 cm identified a large group of 
women (48%) at very low risk of adverse outcome (1.8%) (Figure 18). We could confirm p53 
abn as an adverse marker, with an almost four times as large risk of recurrence or progression 
(HR 3.9, 95% CI 1.3—11.1), when adjusted for age, waist circumference, histotype and grade 
and ultrasound tumor extension, tumor size, endometrial-myometrial junction, color score 
and vascular pattern (Table 14) and with worse survival outcomes.  
To the best of our knowledge, this is the first time an association between increased waist 
circumference and risk of tumor recurrence or progression has been shown (waist 
circumference ≥ 88 cm: adjusted HR 2.6, 95% CI 1.2 —5.6) (Table 14). In contrast, we found 
no increased risk with increasing BMI, which might indicate that the body constitution 
matters, with an increased risk of adverse outcome in abdominal adiposity.  
The conclusions that can be drawn from Study IV must be viewed in relation to the fact that 
ProMisE was analyzed on the hysterectomy specimen and used as a proxy for ProMisE on 
preoperative biopsy, which could affect the results, even if high concordance between biopsy 
and hysterectomy specimen has been reported repeatedly133, 135, 136. 
5.4 YES, SIZE MATTERS 
Tumor size on MRI12, 175, hysterectomy specimen5, 6, 10, 11, 13, 15, 17-19, 23, 24 and ultrasound66, 69, is 
predictive of deep myometrial invasion69, 175, high-risk disease66, lymph node metastases5, 6, 10-
13, 15, 17-19, 23, 24, 69, 175 and recurrence and survival6, 11, 175 and poses an important prognostic 
factor in endometrial cancer. In spite of this, tumor size is not included in the ESMO 
classification27, the GOG-99 criteria140, the SEPAL criteria38 or the PORTEC 1 criteria139, as 
opposed to the Mayo criteria6 and the Mayo-modified criteria143.  
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In Study III, we verified that ultrasound tumor size is predictive of lymph node metastases, 
as a 0.25 increase in AP tumor/uterine diameter ratio increased the odds of lymph node 
metastases with 49% (adjusted OR 1.49, 95% CI 1.13—1.97), when all other variables were 
taken into account (Table 12).  
In Study IV, larger tumor size, as defined by AP diameter ≥ 2 cm, was an adverse factor, 
associated with deep myometrial invasion, lymph node metastases, worse survival and a 
higher risk of recurrence or progression, also among women with preoperative ESMO low 
risk. The risk of recurrence or progression was almost five times as large for tumors with AP 
diameter ≥ 2 cm (HR 4.7, 95% CI 1.8—12.4), when adjusted for age, waist circumference, 
histotype and grade, ProMisE and ultrasound tumor extension, endometrial-myometrial 
junction, endometrial morphology, color score and vascular pattern (Table 14), verifying that 
tumor size is predictive of adverse outcome and showing that ultrasound can be used to assess 
this adverse factor already before surgery.  
5.5 WHY INTEROBSERVER REPRODUCIBILITY IS IMPORTANT 
It does not matter how accurate a diagnostic test is, if users cannot agree on the result. Since 
Study I, an additional interobserver reproducibility study on ultrasound staging has been 
published, and showes that 2D ultrasound predicts deep myometrial invasion and cervical 
stromal invasion with higher interobserver reproducibility than 3D volume contrast imaging 
(deep myometrial invasion: κ 0.41 vs. κ 0.31 and cervical stromal invasion: κ 0.55 vs. κ 
0.45)177.  
When summarizing the results of reproducibility studies on endometrial cancer staging, for 
the assessment of myometrial invasion, interobserver reproducibility has been found to be 
moderate for ultrasound177, 178, fair to good for MRI96-98 and good to very good for 
histopathology99, 101. For the assessment of cervical stromal invasion, interobserver 
reproducibility has been found to be moderate for ultrasound177, 178, moderate to good for 
MRI96, 97 and moderate for histopathology100. Interobserver reproducibility has been found to 
be good to very good for histotype78 and fair to good for grade78, 102. Agreement between 
preoperative biopsy and histotype has been found to be very good for endometrioid cancer107, 
non-endometrioid cancer107 and ProMisE133, 136, but only moderate for grade107. Hence, there 
are limitations in interobserver reproducibility in preoperative imaging, in histopathological 
classification and staging and in the agreement between preoperative biopsy and final 
diagnosis. Based on these findings, it can be argued that risk assessment should not be based 
on grade and that new systems, such as the use of molecular markers, should be evaluated, 
both for risk assessment and classification of endometrial cancer.  
5.6 WHAT IS THE ROLE OF ULTRASOUND IN THE SENTINEL NODE ERA? 
Sentinel node biopsy has emerged as an alternative to complete lymphadenectomy26, to 
obtain staging information while reducing morbidity. The risk of lymphedema after 
lymphadenectomy is 18%—24%179, 180, while only 1.3% using sentinel node biopsy179. 
According to two meta-analyzes, the sensitivity of sentinel node biopsy to detect metastases 
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was 94% (95% CI 91—96)181 vs. 96% (95% CI 91—98)182 and the NPV 100% (95% CI 
99—100)181 vs. 100% (95% CI not stated)182. However, bilateral pelvic sentinel node 
detection rate was only 61% (95% CI 56—66)181 vs. 50% (95% CI 44—56)182, resulting in a 
need for additional bilateral or side-specific lymphadenectomy to obtain complete surgical 
staging in the cases with mapping failure. Also, sentinel node biopsy is not accessible 
everywhere.  
The risk prediction model in Study III can be used to decide when to perform sentinel node 
biopsy or lymphadenectomy, depending on the predicted risk of lymph node metastases. It 
can also be used as a preoperative complement to sentinel node biopsy, to guide whether or 
not to continue with uni- or bilateral lymphadenectomy in the case of mapping failure.  
In Study IV we could identify a very low-risk group for recurrence or progression (1.8%), 
constituting half of the study population (48%) by assessing ultrasound tumor AP diameter (< 
2 cm) and p53 status (non-p53 abn). It can be argued that not even sentinel node biopsy might 
be necessary in such very low-risk cases.  
Theoretically, if preoperative risk assessment was good enough to correctly identify all 
women with lymph node metastases, both sentinel node biopsy and lymphadenectomy could 
be omitted. Moreover, the value of lymph node assessment on survival is uncertain. If studies 
would show that knowledge on lymph node status after lymph node dissection has no value 
in tailoring the adjuvant treatment, both preoperative risk assessment and sentinel node 
biopsy/lymphadenectomy could be omitted. However, ultrasound would still have value in 
the preoperative work up, by identifying women with extrauterine spread, where modified 
surgery is warranted, or in the discrimination of primary cervical cancer or synchronous 
ovarian cancer, where tru-cut biopsy can be diagnostic. 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 STUDY DESIGN 
The major strength of the included studies (Study I—IV) is the origin of study participants, 
from the largest prospective multicenter cohort of endometrial cancer to date. Ultrasound was 
performed by expert examiners, using a standardized ultrasound protocol, resulting in high 
quality ultrasound data. The prospective gathering of pre-defined demographic variables 
resulted in comprehensive demographic data. The use of data capture software assured 
completeness of records on demography, ultrasound and surgery, as the software did not 
allow saving of incomplete forms. The size and the multicenter nature of the cohort increase 
the likelihood that results are generalizable.  
A limitation of Study I was the use of off-line videoclips instead of live ultrasound 
examinations. As an identical material is required to evaluate interobserver reproducibility, 
all ultrasound experts and gynecologists needed to assess the same women. Granted the 
number of assessors, from various countries, live examination would have been ethically 
questionable and not practically feasible.  
The off-line setting, with videoclips collected by an ultrasound expert, might have facilitated 
the assessment for the gynecologists, by guiding them to the region of interest. In spite of this 
possible advantage, gynecologists still had lower interobserver reproducibility than 
ultrasound experts in the assessment of cervical stromal invasion.  
A limitation of Study II is the absence of a centralized pathology slide review for the 
presence of MELF. However, international transportation of pathology slides from various 
counties had been difficult to perform and was not included in the approval by the Ethics 
Committee. Also, the multicenter nature of the data was thought to increase the 
generalizability of the results.  
A limitation of Study III is the missing of outcome data on half of the model development 
population. However, due to guidelines on lymphadenectomy at the time, and the absence of 
sentinel node biopsy for lymph node data also in low-risk women, complete outcome data on 
a general population had not been obtainable.  
A limitation of Study IV was analysis of ProMisE on the hysterectomy specimen and not the 
preoperative biopsy. Though publications report high concordance between ProMisE analysis 
on hysterectomy and biopsy specimen, and all other variables were obtained from 
preoperative data, we do not know if and how results could have varied had ProMisE analysis 
been performed on the biopsy specimen, which limits the conclusions that can be drawn from 
this study. 
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6.2 SELECTION BIAS 
Selection bias occurs when the association of an exposure and an outcome differs between 
subjects included in the study and the overall population, resulting in a sample that does not 
accurately reflect the target population.  
There is no registration on how many women that were eligible for inclusion in the IETA 4 
study cohort, constituting the basis for all studies (Study I—IV) in this thesis. Some women 
with presumed cancer limited to the corpus uteri might not have been referred to preoperative 
ultrasound staging, with a possible over representation of women with grade 3 endometrial 
cancer or non-endometrioid cancer on preoperative biopsy, where lymphadenectomy would 
have been indicated regardless of the ultrasound result, and of women to old or to sick for 
lymphadenectomy, creating a possible selection bias towards a low-risk sample.  
Within the IETA 4 study cohort, lymphadenectomy was more often performed in women 
classified as high risk for lymph node metastases, leading to a selection bias where women 
with known lymph node status constitute a high-risk sample. Indeed, women subject to 
lymphadenectomy in Study III had more cases of deep myometrial invasion on ultrasound, 
more often grade 3 endometrioid or non-endometrioid cancer and higher tumor stage, 
compared to those not subject to lymphadenectomy. A model developed on only the cases 
with complete outcome data would have been subject to bias induced by these systematic 
differences. To adjust for systematic differences and to create a risk prediction model 
applicable on all women, and not only those with high risk, lymph node status was multiply 
imputed when missing.  
6.3 CLASSIFICATION BIAS 
Classification bias, also called measurement or information bias, results from improper 
measurement of exposure or outcome variables. The time between ultrasound examination 
and surgery can possibly have created a classification bias, as there is a chance of disease 
progression between the two events, with subsequent underestimation of ultrasound to 
correctly classify cases. The effect of this was mitigated by the exclusion of all women from 
the IETA 4 study cohort with three months or more between ultrasound examination and 
surgery.  
Deep myometrial invasion and cervical stromal invasion in the hysterectomy specimen is 
assessed through subjective evaluation, with varying interobserver reproducibility. This 
indicates the possibility of classification bias in Study I and Study II, where cases with 
possible wrong classification of deep myometrial invasion and cervical stromal invasion 
according to histopathology still were used as gold standard in the evaluation of ultrasound 
staging.  
In Study II, possible differences in evaluation of MELF status within and between centers 
were mitigated through the use of reference pathologists only and by text and image 
examples, still the presence of the MELF pattern varied between centers. As study 
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populations did not differ regarding tumor stage, cervical stromal invasion, deep myometrial 
invasion or lymph node metastases between centers more or less prone to diagnose the MELF 
pattern, the difference in MELF status could be attributed at least partly to classification bias. 
Tumor size measurements (Study II-IV) should be interpreted with some caution, as most 
women had undergone various endometrial biopsy procedures before ultrasound 
examination, with possible subsequent underestimation of actual tumor size.  
Women subject to lymphadenectomy in Study III had higher tumor stage, consistent with 
lymphadenectomy being performed more often in women with high-risk disease. However, 
stage migration occurs in women with presumed endometrial cancer limited to the uterus, 
when lymphadenectomy is performed and reveals lymph node metastases, compared to if 
lymphadenectomy had not been performed and the existing lymph node metastases had not 
been found. It is possible that the difference seen in tumor stage between women subject to 
and not subject to lymphadenectomy may also have been affected by misclassification.  
The histopathologic assessment of lymph nodes in Study II and Study III was performed 
through conventional sectioning and not through ultrastaging. Possibly could more cases with 
lymph node metastases have been found if ultrastaging had been used, providing better power 
to find a possible adjusted association between the MELF pattern and the presence of lymph 
node metastases (Study II) and enabling the use of more variables in the model building 
(Study III) without increased risk of overfitting. 
6.4 CONFOUNDING 
Confounding occurs when the apparent association between an explanatory variable and the 
outcome is affected by the relationship of a third variable, which is associated with the 
explanatory variable and casually related to the outcome183. A major challenge when building 
logistic regression models is to select which variables to include. A model with many 
variables presents less statistical power, and significant relationship between an explanatory 
variable and the outcome may be missed. Also, the results, including significant existing 
associations or not, depend on which level within a variable that is chosen as reference 
group166. In a RCT, the randomization process compensates for known and unknown 
confounders by dividing them evenly in the groups.  
When assessing the relationship between the explanatory variables and the outcome in Study 
II (MELF and higher stage or lymph node metastases), Study III (preoperative variables and 
lymph node metastases) and Study IV (preoperative variables and recurrence or progression), 
constituting cohort studies, there is always the possibility that confounding variables affected 
the outcome, and that variables not included in the regression models could have posed an 
important effect on the outcome. 
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6.5 EXTERNAL VALIDITY 
External validity refers to the extent to which the results of a study can be generalized to 
another population. The results of Study I are applicable only to off-line settings, whereas the 
results of Study II—IV are applicable to settings where ultrasound is performed by 
ultrasound experts, using high-end equipment. 
In Study III, we excluded women originating from a center with a screening population from 
the model development cohort, to increase the generalizability of the model developing 
cohort to the general population. When creating a risk prediction model, like in Study III, an 
important consideration is the complexity of the model relative to the available sample size. 
Overly complex models are often overfitted, and perform well on the model development 
data but poorly on new data. Except for overfitting, another threat to external validity is 
"apparent" model validation, where the predictive performance has been assessed on the same 
data set that was used for model development. In Study III, overfitting was prevented by 
selecting predictors of lymph node metastases a priori instead of data-driven, by using a 
limited set of predictors to yield 10 events per predictor, and by using a heuristic shrinkage 
factor to get the final prediction equation. The large sample size, the multi-center design and 
the results from "leave-center-out-cross-validation", mimicking external validation, suggests 
good generalizability of the model.  
When developing a risk prediction model, the development cohort should be representative of 
the intended target population for the model, unlike the case in models created on 
retrospective cohorts, consisting only of women that were subject to lymphadenectomy. The 
multiple imputation used in Study III enabled model development on all women and limited 
the effect of selection bias. However, the result of multiple imputation, and hence the external 
validity of the risk prediction model developed on the imputed cohort, depends on how well 
the imputation was performed. Though professional statisticians performed the multiple 
imputation, using established methods that were aided by the availability of auxiliary 
variables such as hysterectomy findings, it can always be argued that not all factors related to 
the outcome were taken into consideration. External validation on an independent cohort, 
preferably with known sentinel node outcomes in cases without lymphadenectomy, is 
warranted before the model can be used in clinical practice.  
Study IV is based on a single center cohort from a general population, as opposed to a high-
risk population from a tertiary referral center. The external validity on a general population is 
assumed to be good, as we have reproduced results from a published validation study in a 
population-based cohort133. 
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7 CONCLUSION 
Study I: 
• Gynecologists and ultrasound experts assessed deep myometrial invasion with 
comparable diagnostic accuracy and interobserver reproducibility. 
• Compared to gynecologists, ultrasound experts assessed cervical stromal invasion 
with greater diagnostic accuracy and interobserver reproducibility. 
• Preoperative ultrasound staging in endometrial cancer is best performed by ultrasound 
experts. 
Study II: 
• Tumors with the MELF pattern were slightly larger, with a higher color score and 
more often the multiple multifocal vascular pattern on preoperative ultrasound.  
• Presence of the MELF pattern did not affect the diagnostic accuracy of deep 
myometrial invasion by preoperative ultrasound.  
• Tumors with the MELF pattern were more than twice as likely to have more 
advanced stage (≥IB) and lymph node metastases. 
Study III: 
• A risk prediction model with variables from endometrial biopsy results, clinical and 
ultrasound characteristics can reliably estimate the individual risk of lymph node 
metastases before surgery in women with endometrial cancer. 
• The risk prediction model is superior to risk classification by endometrial biopsy 
alone or in combination with ultrasound. 
Study IV: 
• The ProMisE p53 abn subtype is an adverse prognostic marker, associated with older 
age, larger tumors on ultrasound, non-endometrioid cancer, higher stage, tumor 
recurrence or progression and worse survival. 
• Ultrasound tumor size < 2 cm and non-p53 abn status have the potential to identify 
women at very low risk of adverse outcome.  
• A model with demographic, sonographic and ProMisE variables had higher ability to 
predict recurrence or progression than the ESMO classification. 
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8 FUTURE PERSPECTIVES 
The role of a classification system for endometrial cancer based on molecular markers should 
be further explored, to obtain a classification with higher interobserver reproducibility and 
higher agreement between preoperative biopsy and hysterectomy specimen than the current 
system based on histotype and grade. 
An external validation study of published preoperative risk models on a large prospective 
cohort, with complete data in all women of all variables included in the models eligible for 
validation, would answer which model that best predicts the risk of lymph node metastases 
and establish if our model can be put into use in clinical routine.  
Further studies are warranted to assess if incorporation of molecular markers to other 
preoperative variables from demography, endometrial biopsy and imaging can improve the 
prediction of lymph node metastases and adverse outcome in risk models and classification 
systems. These studies should be preceded by interobserver reproducibility studies on eligible 
predictive variables, to obtain robust risk models and classification systems. 
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